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 ABSTRACT 
Nanomedicine has recently emerged as an exciting tool able to improve the early 
diagnosis and treatment of a variety of intractable or age-related brain disorders. The 
most relevant properties of nanomaterials are that they can be engineered in such a way 
that they can cross the blood brain barrier, with the final aim of targeting specific cells 
and molecules and to act as vehicles for drugs. Potentially beneficial properties of 
nanotherapeutics derived from its unique characteristics include improved efficacy, 
safety, sensitivity and personalization compared to conventional medicines. 
In this review, recent advances in available nanostructures and nanomaterials for brain 
applications will be described. Then, the latest nanotechnological applications for the  
treatment and diagnosis of neurological disorders, mainly brain tumors and 
neurodegenerative diseases, will be reviewed. Recent investigations of the neurotoxicity 
of the nanomaterial both in vitro and in vivo will be summarized. Finally, the ongoing 
challenges that have to be meet if new nanomedical products are to be put on the market 
will be discussed and some future directions will be outlined. 
 
Keywords: Alzheimer’s disease, brain tumors, diagnosis, engineered nanomaterials, 
nanoscience, nanotechnology, Parkinson’s disease 
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 1 INTRODUCTION 
Nanomedicine can be defined as the use of nanostructured materials in medicine that 
have some exceptional medical effects due to their structure,like passive targeting to 
tissues or the capability to cross some biological barriers, for instance  [1]. Approaches 
to nanomedicine range from the medical use of nanomaterials to nanoelectronic 
biosensors, and even possible future applications of molecular nanotechnology. Besides 
the established therapeutic modes of action, nanomaterials are opening up new options 
in cancer therapy, such as photodynamic and hyperthermia treatments. Furthermore, 
nanosized carriers are also capable of avoiding some drug delivery problems, that could 
not be effectively solved in the past and which include overcoming multidrug-resistance 
phenomenon and penetrating cellular barriers that limit drug accessibility to intended 
targets, such as the blood–brain barrier (BBB), among others [2].  
One of the most promising aspects of nanotechnology is that it has the potential to 
change the way brain drug delivery is approached. Thus, nanomedicines might be 
advantageous for the treatment and diagnosis of a number of central nervous system 
(CNS) disorders including brain tumors or neurodegenerative disorders that are 
nowadays a major medical challenge (Figure 1) [2]. However, due to the 
physicochemical properties that these nanomaterials present, namely their large surface 
area, they may cause neurotoxicity after entering into the brain. As a result, there is an 
important need to assess their potential neurotoxic effects on the CNS function, as 
specific pathways and mechanisms through which these nanomaterials may produce 
their toxicity remain unknown. In this review, current advances in available 
nanostructures and nanomaterials for brain applications will be described.  
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Then, the latest nanotechnological applications for the  treatment and diagnosis of 
neurological disorders, mainly brain tumors and neurodegenerative diseases, will be 
reviewed. Furthermore, recent investigations of the nanomaterial neurotoxicity both in 
vitro and in vivo will be summarized. Finally, the ongoing challenges facing those who 
aim to put nanomedical products on the market will be discussed and some future 
directions will be outlined.  
1.1 ADVANCES IN AVAILABLE NANOSTRUCTURES AND 
NANOMATERIALS FOR NEUROSCIENCE  
Various nanomedicines can be used in targeted delivery of drugs across the BBB, 
neuroprotection and neural regeneration. This section provides a summary of 
nanostructures and nanomaterials that are able to show progress in the diagnosis and 
treatment of brain disorders. The variety of structures and materials discussed below 
allows the selection of the better nanosystem for a specific CNS disorder.  
Nanostructures used for the development of nanomedicines for brain disorders include 
(Figure 2):  
Nanoparticles (NP) NP for pharmaceutical purposes are solid particles ranging in size 
from 1 to 1000 nm made of macromolecular materials in which the active principle 
(drug or bioactive material) is encapsulated, or to which the active principle is attached 
or adsorbed [3]. NP can be prepared using several materials such as natural and 
synthetic polymers, metals or lipids. They can be functionalized with targeting ligands 
or antibodies to cross the BBB and selectively target specific cells. Among lipid NP, 
different types can be found. Solid lipid nanoparticles (SLN) are colloidal carriers 
constituted by a solid lipid matrix at room and body temperature, composed of 
physiological lipids (lipid acids, mono-, di-, or triglycerides, glycerine mixtures, and 
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waxes), and stabilized by biocompatible surfactants (nonionic or ionic) [4]. 
Nanostructured lipid carriers (NLC) are developed by the creation of a lipid particle 
matrix as imperfect as possible in order to accommodate the active molecules in its 
core. To achieve this aim, a mix of solid and liquid lipids is used to produce NP that 
remain solid at temperatures up to 40 ºC. NLC present considerable crystal disorder, 
translated into a higher drug loading and less drug expulsion during storage [5]. 
Nanoliposomes. These are biocompatible nanoscale lipid vesicles composed by double 
phospholipid layers which may entrap aqueous solutions. They have structural 
flexibility in size, composition and bilayer fluidity as well as capability to entrap both 
hydrophilic and hydrophobic compounds [6, 7]. Furthermore, they provide an exclusive 
chance to transport actives into cells or even inside individual compartments. Inherent 
problems include poor stability. Polyethylene glycol (PEG) is commonly used to 
modify their surface, reducing opsonization in plasma and decreasing its recognition 
and removal. Targeted therapy through the brain can also be achieved using PEGylated 
nanoliposomes vectorized with monoclonal antibody to glial fibrillary acidic proteins, 
TfR (OX26) or human insulin receptor.  
Lipid-polymer hybrid NP. These new NP combine the positive features of liposomes 
and polymeric NP while avoiding some of their drawbacks. They consist of a 
hydrophobic polymeric core, a lipid shell surrounding the polymeric core, and a 
hydrophilic polymer stealth layer outside the lipid shell [8]. 
Nanomicelles. Nanomicelles are obtained when amphiphilic molecules spontaneously 
assemble in aqueous media to form core-shell vesicles [9]. In addition to surfactants, 
amphiphilic block copolymers are generally used for preparing nanomicelles. Notably, 
they can solubilize poorly water-soluble drugs and their surface can be functionalized 
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for targeted delivery. However, due to their fragile structure, preparing long-circulating 
nanomicelles and sustained-release nanomicelles is challenging. 
Dendrimers. These are highly organized nanoscale sized 3D structures with repeatedly 
branched polymers that arise from a central core that provides a high degree of surface 
functionality and versatility and that can also be loaded with drugs [10]. Targeted 
delivery is also possible via targeting ligands conjugated to the dendrimer surface.  
Carbon nanotubes. Carbon nanotubes (CNT) are biodegradable nanometer-diameter 
cylinders consisting of a single graphene sheet wrapped up to form a tube [11]. CNT 
behave like nano-needles and pass through the cell membrane through a spontaneous 
and still unclear mechanism [12]. Therapeutic and diagnostic agents can be 
encapsulated, covalently attached or absorbed on the surface of CNT. However, their 
biomedical applications arise serious concerns and CNT toxicity remains a topic of 
debate. CNT may cause pulmonary inflammation and fibrosis [13]. Another common 
hurdle when working with this nanosystem is their low dispersibility due to their 
tendency to aggregate. 
Nanogels. Nanogels are nanosized networks of physically or chemically cross-linked 
polymers that swell in a appropriate solvent. They have high drug loading capacity [14]. 
Up to now, liposomes and polymeric NP have been the most generally exploited 
nanostructures for brain applications. Most FDA-approved nanomedicines were 
developed using these two nanosystems. 
Regarding materials, an important major requirement for brain delivery systems is a 
rapid biodegradability. A degradation time frame from a few days to a few months is 
preferable. Thus, non-degradable particles such as fullerenes, metal particles, quantum 
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dots or potentially risky CNT would not be the first option. Most of the FDA approved 
systems are liposomes or lipid-based systems. Lipids, due to their resemblance to in 
vivo components, are well tolerated in the organism and are less toxic than other 
materials. Among polymers, three types of polymer materials in particular appear to be 
the materials of choice: (1) poly(alkyl cyanoacrylates) (PACA) such as poly(butyl 
cyanocrylate) (PBCA) or poly(isohexyl cyanoacrylate) (PIHCA), (2) poly(lactic acid) 
(PLA) or its copolymer (lactide-co-glycolide) ( PLGA), (3) chitosan. PLGA remains the 
most widely used material for NP development for brain treatment because of its 
biodegradability, biocompatibility, ease of processing and FDA-approval [15]. Other 
polymers extensively studied in nanotechnology applied to the CNS delivery of drugs 
are PACA [15]. Among them, PBCA is the fastest biodegrading material. Although 
some of these polymers have been described to be devoid of toxicity, they are not 
currently approved by the FDA for i.v. administration. Chitosan is one of the most 
widely used polysaccharides in the design of nose to brain drug delivery systems due to 
its special mucoadhesive and absorption enhancer properties and its great safety [16]. 
Concerning metals, principally iron, gold and silver are being investigated as magnetic 
resonance imaging (MRI) contrast enhancers and photosensitizers for diagnosis of brain 
disorders [17]. A concern with metallic NP is the possible toxicity due to the risk of 
retention from repeated exposure [17]. Studies addressing these issues are discussed in 
section 3. On the other hand, there has been a lot of research done in the field of 
materials proposing new candidates for biomedical applications. Novel polymers 
investigated for brain disorder therapy include block copolymers such as Pluronic block 
polymers based on ethylene oxide and propylene oxide which are able to improve the 
delivery of a wide spectrum of drugs across the BBB [18, 19] or polymer drug 
conjugates such as PEG-proteins or N-(2-hydroxypropyl)methacrylamide (HPMA)-
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drugs [20, 21]. An innovative approach is the use of natural polymers or recombinant 
protein-based polymers (silk like proteins [22] or elastomer like proteins [23]) to obtain 
nanocarriers with excellent biocompatibility and biodegradability and low 
immunogenicity. New improvements will certainly come from stimuli-responsive 
polymers that allow targeting the drug to its site of action followed by on-demand drug 
delivery [24]. Finally, multifunctional materials able to perform in vivo diagnosis and 
release the targeted drug according to the correct time schedule might also be expected 
[25]. 
1.2 PROBLEMS ASSOCIATED WITH BRAIN DELIVERY: BLOOD BRAIN 
BARRIER  
The penetration of the CNS by drugs remains a key issue to improve, in order to treat 
CNS disorders. . According to pharmacokinetic data estimated by different authors , 
drugs employed for diagnostic or therapeutic purposes are characterized for exhibiting 
high non-specific binding, and low residence time in the blood plasma [26]. As a result, 
the percentage of the administered drug that reaches the brain is quite low. Furthermore, 
the incorporation of drugs into the CNS is further hampered by the presence of the BBB 
[27]. 
The BBB is a structure composed by a complex system of endothelial cells,  pericytes, 
astroglia and perivascular mast cells, which prevents the passage of most circulating 
cells and molecules (Figure 3) [28]. The compact network of interconnections confers a 
transelectrical resistance >1500 Ωcm2 on the endothelial layer of the BBB, which is the 
highest among all endothelial districts [29]. This complex structure prevents the brain 
uptake of most drugs, except for highly hydrophobic compounds with a mass lower than 
400–600 Da and small hydrophilic compounds with a mass lower than 150 Da, which 
are able to get across the membrane by passive diffusion [30]. Opiates, anxiolytics, 
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selective serotonin reuptake inhibitors and antipsychotics are some of the drugs that can 
cross the BBB. However, most antitumor agents and antibiotics cannot. As a result, the 
tightness of the BBB prevents pharmacological therapy in the case of many 
neurological disorders. Furthermore, it should be also taken into account that the 
existence of the P-glycoprotein (P-gp) pump in the BBB represents a further obstacle 
for drugs when it comes to crossing the cerebral capillary endothelium and enter the 
brain parenchyma. This P-gp complex allows the recognition of molecules necessary to 
be incorporated in the brain and the exclusion of other molecules, drugs included [31]. 
The BBB protects the CNS from molecules circulating in the blood that may be 
neurotoxic. These substances may be xenobiotics acquired from the environment, taken 
in the diet or endogenous metabolites or proteins. The key feature of the BBB are the 
‘tight junctions’ (zonulae occludentes) which significantly reduce permeation of polar 
solutes between the endothelial cells from the blood plasma to the brain extracellular 
fluid through paracellular diffusional pathways [28, 32]. The tight junctions are 
responsible for the restriction of the paracellular diffusional pathway between the 
endothelial cells to ions and other polar solutes, and effectively block penetration of 
macromolecules by this route. This is of great importance as the adult CNS has been 
observed not to have regenerative capacity if it gets damaged and, therefore, fully 
differentiated neurons are not capable of dividing and replacing themselves under 
normal circumstances [33]. As a result, any increased entry of neurotoxins into the brain 
might increase the rate in the natural speed of cell death, which would be rather 
negative. The maintenance of many BBB properties depends on a narrow association 
with astrocytes. Furthermore, ABC energy-dependent efflux transporters (ATP-binding 
cassette transporters) dynamically pump many of the neurotoxic agents out of the brain 
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[34, 35]. These transporters are oriented in such a way that favor transport of molecules 
into or across the endothelial cell from blood to brain or viceversa.  
However, most therapeutic molecules are delivered across the BBB via the receptor-
mediated transcytosis system. This procedure involves receptor-mediated endocytosis at 
the blood side followed by intracellular movement and exocytosis at the brain side of 
brain endothelial cells [36]. Several receptors on the BBB, such as the transferrin (Tf) 
receptor (TfR), low-density lipoprotein receptor (LDLR), insulin-like growth factor 
receptors 1 and 2 (IGFR1 and 2) and the insulin receptor (IR) , among others, have been 
widely studied as part of the transcytosis system. This receptor-mediated transcytosis 
allows large molecules to be transported across the BBB and, therefore, it is a useful 
method for the delivery of proteins, peptides and certain peptidomimetic monoclonal 
antibodies into the brain. This is why biopharmaceuticals, like recombinant proteins,  
have gained interest as potential agents for the treatment of CNS diseases over the last 
decades. However, in order to become applicable, they need a brain targeting moiety 
because, as it has been observed for other drugs, they cannot effectively reach the brain 
[37]. 
1.3 CENTRAL NERVOUS SYSTEM DELIVERY APPROACHES 
Over the past decades, there have been many important achievements in drug discovery, 
from small molecules to biopharmaceuticals like recombinant proteins or antisense 
medicines. These molecules have gained interest as future possible agents for the 
treatment of different CNS diseases [38]. Nevertheless, these potential drugs are not 
able to get to the brain in effective amounts, due to the BBB as described above, so they 
need a brain targeting modality that will enable their use for such therapies [39]. Current 
existing approaches to deliver drugs to the brain are commonly divided into either 
invasive or non-invasive methods.  
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1.3.1 Invasive methods 
A) Disruption of the BBB 
Several invasive methods have been used in the past, like the direct intracerebral 
infusion of the drug [40] or the hyper-osmotic opening of the BBB by the use of a 
hypertonic solution of mannitol or urea, which it is known to open the tight junction 
network momentarily, as the capillary endothelial cells shrink by the induction of water 
efflux. As a result, drug compounds could cross the BBB as the paracellular flow was 
considerably increased. This procedure has been successfully applied to increase the 
BBB permeability for CNS active drugs in animals [41]. However, we have to take into 
account that the defense mechanism of the brain is altered due to these procedures, that 
increase its vulnerability to circulating chemicals or toxins. On the other hand, BBB can 
also be disrupted by the use of drugs. Cytotoxic agents like etoposide and cisplatin have 
been found to create openings between endothelial cells by disrupting tight junctions 
[42]. In a similar way, vasoactive agents like angiotensin II, peptidase inhibitors or 
bradykinin can also affect BBB permeability temporarily. These techniques might be 
frequently accompanied by some systemic side effects as the enhancement of the 
penetration of drugs into the CNS via the circulatory system will also increase the 
penetration of drugs throughout the entire body [43]. 
B) Direct implantation 
The problems linked with the side effects of systemic drug delivery and the necessity to 
modify the surface of the delivery vehicle to make it able to cross the BBB can be 
avoided with the use of implantable local nanomaterials. Furthermore, these 
nanomaterials allow to reach much higher local drug concentrations compared to 
traditional approaches as drug is delivered directly to the targeted tissue. Gliadel®, 
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which is at present used in the clinic, consists of polyanhydride polymer wafers 
impregnated with bischloroethylnitrosourea (BCNU, carmustine) that are located in the 
resection cavity after the excision of the tumor [44]. This technology is considered the 
gold standard for intra-cerebral drug therapy [45]. Clinical trials have shown that the 
combination of  Gliadel® with surgery and radiation increases survival of GBM patients 
up to fifteen months. Furthermore, as paracrine administration of interleukin-2 produces 
a potent antitumor immune response and improves survival in animal brain tumor 
models, Rhines et al. observed a synergistic antitumor effect in the combination of 
microspheres containing interleukin-2 and Gliadel® biodegradable polymer wafers, 
when they were both directly implanted at the site of an intracranial rat glioma [46]. 
Convection-enhanced delivery (CED) is a novel approach to deliver drugs directly into 
brain tissue and is defined as the continuous injection of a therapeutic fluid agent under 
positive pressure. In order to deliver drugs that would be too large to diffuse over 
required distances and would not cross the BBB, this technique was introduced by 
researchers from the US National Institutes of Health (NIH) by the early 1990s [47]. 
Using this approach, compounds employed for CNS disorders including 
chemotherapeutic agents, nanomaterials and macromolecules can be easily delivered 
with dose adjustment and minimal invasiveness [48-51]. Some nanocarriers that have 
already been injected by CED are nanoparticles (lipidic, polymeric or magnetic),  
liposomes,  polymeric micelles and dendrimers (see Table 1) [50, 52-56]. Huynh et al. 
observed that the treatment by CED with ferrociphenol-loaded lipid nanocapsules 
significantly increased the survival time of intracranial 9L rat gliosarcoma tumor-
bearing rats in comparison with an untreated group [52]. Similar results were obtained 
by Bernal et al. with temozolomide-loaded polymeric nanoparticles [50]. Dickinson et 
al. studied the infusion of liposomes by CED in canine healthy brains [56]. A mixture of 
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liposomes loaded with Gd and with CPT-11 was injected as a potential treatment 
strategy by CED. Results showed that liposomes presented a robust distribution volume 
in both gray and white matter, with minimal adverse effects. 
Stereotaxy, or stereotactic surgery, is a type of minimally invasive brain surgery that 
uses a system of three dimensional coordinates to locate a site within the brain. It 
requires only a small incision and a hole less than 12.5 mm in diameter to be made in 
the skull, which is usually performed under local anesthesia. The stereotactic operation 
has been commonly employed in the field of neurosurgery to perform injections, 
implantations, stimulation and biopsies [57, 58]. Traditionally, frame-based techniques 
were the standard method used and more recently, frameless stereotaxy or 
neuronavigation has been introduced [59, 60]. One relevant aspect of stereotactic 
surgery is that drugs can be easily administered in precise, discreet and functional areas 
in the brain, without causing any damage in the surrounding tissue. Injections can be 
repeated if necessary. Most probably, the main disadvantage of local drug delivery 
administration is that the dosage cannot be adjusted after brain implantation [61]. 
All these methods present advantages, but on the other hand we have to take into 
account the degree of invasion of the techniques, which make them less patient friendly 
and more laborious, and which requires skill to avoid possible permanent damage to the 
brain. As a result, some alternative non-invasive methods have been proposed. 
1.3.2 Non-invasive methods 
A) Nasal delivery 
Some macromolecular drugs like peptides and proteins, also called “biologics”, are too 
hydrophilic and large to move across the BBB from the systemic circulation [62, 63]. 
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Furthermore, if these drugs are taken orally, they would be quickly degraded by GI 
enzymes before they were absorbed or by liver cytochromes. For these particular cases, 
a non-invasive therapy, like the intranasal route, is desirable for chronic patients 
suffering from PD or AD [64-66]. The extensive interest in intranasal route for 
therapeutic purposes arises from the particular anatomical, physiological and 
histological characteristics of the nasal cavity, which provides potential for rapid 
systemic drug absorption and quick onset of action via the unique connection of 
olfactory and the trigeminal nervous system between the brain and the external 
environment [67, 68]. Although less than 5% of the nasal cavity is occupied by 
olfactory epithelium, this route is direct, bypassing the BBB, since the olfactory neurons 
do not present a synapse between the receptive element and the afferent path [69, 70]. 
Therefore, drugs across olfactory epithelial cells may simply move slowly through the 
tight interstitial space of cells, or across the cell membrane by endocytosis, or 
transported by vesicle carriers and neurons [71]. Besides, intranasal absorption enhances 
drug bioavailability in comparison with that obtained after GI absorption, as the GI and 
hepatic presystemic metabolism is avoided [72, 73]. The delivery of a drug directly into 
the CNS is determined by a combination of biological and molecular characteristics of 
the drug. In animal models it has been observed that when the molecular weight (MW) 
(above 20 kDa), the degree of ionisation and the hydrophilicity of the drug is increased 
the drug transport into the CNS after intranasal administration can be reduced [67]. 
Furthermore, the enzymatic degradation in the olfactory epithelium or the P-gp pumps 
at the apical membrane surface also affect small MW drugs  [74]. However, when 
nanomaterials are used for the delivery of actives across barriers, the transport is no 
longer dependent on the drug properties, but in the properties of the delivery system 
[75]. The main mechanism of uptake of nanomaterials (when larger than about 20 nm) 
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in nose-to-brain drug delivery is thought to be transcellular; however, the transcellular 
and paracellular routes of cell transport are also present [76]. The incorporation of 
mucoadhesive polymers into nasal formulation can increase the mucosal contact time 
and prolong the residence time of the dosage forms in the nasal cavity [73]. As we have 
previously commented, chitosan has been extensively studied for nose-to-brain delivery 
due to the non-toxic nature and its absorption enhancing and mucoadhesive properties 
of the delivery systems [77]. Chitosan can be formulated in combination with other 
polymers, like hydroxylpropylmethyl cellulose, as a mucoadhesive temperature-
mediated in situ gel to enhance intranasal delivery of drugs like ropinirole, the 
dopamine (DA) D2 agonist, to the brain for the treatment of PD [78]. Similarly, 
Pardeshi et al. observed that when the same drug was loaded into polymer-lipid hybrid 
NP and administered intranasally, the therapeutic activity obtained with this formulation 
was comparable to that with the marketed oral formulation of ropirinole [79]. Along 
with the mucoadhesive polymers, lectins have been conjugated to bioadhesive systems 
in order to improve drug absorption through nasal mucosa. Lectins can specifically 
recognize carbohydrates and, therefore, bind to the glycosylated nasal mucosa. [80]. 
Gao et al. developed a PEG-PLA based system coupled with the lectin wheat germ 
agglutinin (WGA), which specifically binds to N-acetyl-D-glucosamine and sialic acid, 
both abundantly observed in the nasal cavity [81]. They showed that the brain uptake of 
a fluorescent marker-coumarin carried by WGA functionalized nanoparticles was about 
2 fold in different brain tissues compared with that of coumarin incorporated in the 
unmodified ones. Recent studies have shown that the lipophilicity of the nanosystem 
also plays an important role in the success of the delivery of the drug to the brain 
through the nose-to-brain barrier in the treatment of a great variety of CNS diseases [65, 
66, 72, 79, 82-84]. Yang et al. confirmed that rivastigmine liposomes improve the brain 
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delivery and enhance pharmacodynamics which respect to BBB penetration and nasal 
olfactory pathway into the brain after intranasal administration [66]. Li et al. observed 
that the efficiency of acetylcholinesterase inhibition of galanthamine when loaded into 
liposomes was greatly enhanced by intranasal administration compared with oral 
administration [65]. 
B) Cell penetrating peptides (CPP) 
Cell-penetrating peptides (CPPs) are a class of short amphipathic and cationic peptides, 
typically with 5–30 amino acids that, unlike most peptides, are rapidly internalized 
across cell membranes [85]. Two decades have passed since the first CPP was 
discoveredand ever since CPPs have been used for a variety of applications, including 
the delivery of molecular cargoes such as liposomes, nanoparticles, imaging agents 
(fluorescent dyes and quantum dots), drugs, oligonucleotide/DNA/RNA and 
peptides/proteins into cells [86-93]. CPP-based delivery systems show a great ability in 
carrying these macromolecules across cellular membranes, combining a low cellular 
toxicity with high efficiency [94]. 
Among the CPPs, TAT, the transactivating protein of the human immunodeficiency 
virus type-1 essential for viral replication, is maybe one of the most frequently used 
CPPs for DDS modification. Its interaction with the negatively charged BBB is favored 
thanks to its cationic charges. As a result, the sequence is endocytosed after the 
permeabilization of the cell membrane via a receptor/transporter independent pathway. 
TAT has been used to improve the delivery of small chemotherapeutic molecules, like 
ciprofloxacin, across the BBB to the brain [95, 96]. Furthermore, CPPs can also be 
attached to nanomaterials in order to enhance the penetration of these across the BBB. 
Qin et al. prepared a TAT-modified liposomal formulation loaded with doxorubicin, 
showing a stronger inhibitory effect against C6 cell lines, higher efficiency of brain 
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delivery, longer survival time of brain glioma bearing animals and lower cardiotoxic 
risk than the free drug [97]. 
Beside TAT, SynB peptides and Angiopeps are the most extensively studied vehicles 
for the delivery of different drugs to the brain [98-100]. Many drugs have been 
conjugated to members of the SynB family of peptides, showing an increase of their in 
vivo activity in the brain [100-103]. Rousselle et al. described that the brain penetration 
of poor brain-penetrating drugs, like doxorubicin, dalargin or benzylpenicillin, was 
significantly increased when the drugs were conjugated to SynB vectors and 
intravenously administered to mice [102, 104, 105]. Angiopeps, a family of Kunitz 
domain-derived peptides, have also been used in both in vitro and in vivo studies to 
transport drugs to the brain in a highly efficient way. Regina et al. reported that a 
member of the angiopep family, Angiopep-2, can transport paclitaxel across the BBB to 
treat brain cancer [106]. This effect was also seen in a study by Che et al., where 
Angiopep-2 bound to doxorubicin and etoposide killed cancer cell lines in vitro with 
apparently similar cytotoxic mechanisms to unconjugated doxorubicin and etoposide, 
but crossing the BBB with a dramatically high influx rate.[107] In recent years, much 
effort has been made to use Angiopeps to deliver drugs or nanoparticles across the BBB 
to the CNS, showing that Angiopep-mediated targeting is one of the most promising 
ways to reach the CNS for treatment of different brain diseases [98] [99] [108-110]. 
C) Drug Delivery Systems 
Drug delivery systems (DDS) have the potential to overcome limitations of drugs such 
as poor solubility, lack of selectivity, toxic side effects and development of multidrug 
resistance [111]. They have been widely studied for the delivery of actives to many 
regions of the body, including the brain [112]. The aim when using nanosized drug 
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carriers in brain delivery is to increase the specificity toward diseased neurons, to 
protect the drugs against enzyme inactivation, and/or to improve their bioavailability by 
increasing their diffusion through the BBB [113]. This can be achieved by an adequate 
engineering to provide tailored functionalities using ordinary procedures in 
nanotechnology. Nanoparticle size and the nature and number of linkers on the NP 
surface can be optimized to control not only both the loading and the release of the 
entrapped or covalently linked drug components, but also the crossing through the BBB 
[114]. DDS can also deliver contrast agents in effective concentrations to the brain, 
improving the efficacy of existing CNS imaging and treatment regimens [115]. 
Furthermore, nanosystems can decrease the overall systemic toxicity and, therefore, 
increase the maximum tolerated dose of the drug by using biocompatible materials that 
avoid the release of the therapeutic agent within non-target tissues [116]. Eventually, the 
drug delivery across the BBB to the desired site of action in the CNS can also be 
manipulated by modifying the surface of the nanosized system, for instance, with CPPs 
[85]. This modification leads to increased therapeutic efficacy due to an increased 
accumulation of the either therapeutic or diagnostic agent in the CNS [117]. 
The uptake of these DDS into the CNS can be attributed to the combination of many 
factors [118]. For instance, the efficacy of polysorbate 80 used as coating agent in 
inhibiting the efflux systems that are present in the BBB, especially P-gp has been 
widely studied in the past [119, 120]. In in vitro studies, Estella-Hermoso de Mendoza 
et al., observed that lipid NP coated with polysorbate 80 were able to reduce the P-gp 
activity, as compared to the same lipid NP without the polysorbate 80 coating. As a 
result of this, polysorbate 80 coated lipid NP showed a significantly higher uptake by 
the rat glioma C6 cell line which is naturally overexpressing P-gp [121]. Another 
hypothesis for the NP uptake was demonstrated with some in vitro experiments by 
18 
 
19 
 
different authors, who observed that apolipoproteins E and/or A-I (apo E or apo A-I) 
were adsorbed on the surface of PBCA nanoparticles coated with polysorbate 80 or 
poloxamer 188 after their incubation in blood plasma [122, 123]. Therefore, they 
concluded that polysorbates and poloxamer 188 act as an anchoring point for 
apolipoproteins, so that they can then interact with lipoprotein receptors on the brain 
capillary endothelial cells. 
As it will be shown in the following sections, many delivery systems have been 
developed along these last years for the diagnosis and treatment of CNS disorders. The 
most representative examples of DDS that have been used to deliver active compounds 
to the brain in vivo are shown in Table 1-4.
2 NANOMEDICINE FOR THE DIAGNOSIS OF NEUROLOGICAL DISORDERS 
The task of evaluating and diagnosing damage to the nervous system is complicated and 
complex. Detection of neurological signs and neuroimaging abnormalities, which appear at 
relatively late stages in the disease, play a major role in current clinical diagnosis. 
Unfortunately, for many CNS diseases, successful treatment mainly depends on early 
detection. Finding potential targets and improving the sensitivity and specificity of currently 
available diagnostic tests are an important topic of current research. An overview of recent 
progress in the field of nanotechnology-based diagnosis for brain tumors and 
neurodegenerative diseases is provided in this section. The most relevant examples are 
included in Tables 1 to 5. The cases below show that nanomaterials have potential to 
overcome the low sensitivity problems faced by current diagnostic tools.  
2.1 Nanotechnology for improving brain cancer diagnosis 
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The World Health Organization (WHO) identifies more than 100 brain tumor types classified 
according to histopathological features, genetics, clinical presentation, and malignancy [124]. 
Malignant brain tumors consist of high-grade primary brain tumors such as malignant gliomas 
and metastatic lesions to the brain from peripheral cancers [124, 125]. It is estimated that in 
the US alone, more than 23,000 men and women will be diagnosed with and 14,000 men and 
women will die of cancer of the brain and other nervous system in 2013 [126]. Among all 
brain tumors, the most common high-grade primary brain tumor in adults is glioblastoma 
[127, 128]. Overall, metastatic brain tumors are the most frequently occurring form of brain 
tumors in adults, as 10% to 20% malignant peripheral tumor patients develop brain metastases 
[125, 129]. Brain tumor diagnosis and grading follow the WHO classification [124]. Glioma 
diagnosis is based on neuroimaging with MRI confirmed by neurological examination or 
encephalography. Neuroimaging has become increasingly important in assessing brain 
tumors. Novel contrast agents allow tumor microvasculature scanning and delineation of areas 
with increased cellularity and vascular proliferation. On the other hand, there is no sensitive 
biomarker for brain cancer diagnosis in plasma at present.  
There are several reports of successful use of nanotechnology to diagnose brain cancers 
(reviewed in Orringer et al. [130] and in Meyers et al. [131]). Major benefits in this area 
include the enhancement of the analytical sensitivity of brain imaging technologies improving 
the detection and delineation of tumor margins, among others. NP have the potential to 
improve both preoperative and intraoperative brain tumor detection. 
Chelated gadolinium (Gd) is the standard T1 MRI contrast agent due to its paramagnetic 
properties [132]. However, it suffers from short blood half-life requiring repeated injections, 
high dosages and false-positive contrast enhancement. Nanotechnology strategies used so far 
for improved cell uptake and retention are the following: (1) Oxide NP have shown to be the 
best at increasing properties of Gd. For instance, Park et al. reported high contrast in vivo T1 
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MR images of the rat brain tumor using ultrasmall Gd oxide NP with a diameter of 
approximately 1 nm with lack of toxicity in vitro [133]. Faucher et al. used ultrasmall Gd 
oxide NP to label GL-261 glioblastoma multiforme cells, in order to localize and visualize 
them in vivo using MRI [134]. More recently, Zhou et al. showed that small-sized zwitterion-
coated Gd-embedded iron oxide (GdIO) NP exhibited a strong T1 contrast effect for imaging 
of tumors through the EPR effect. Zwitterion coating may reduce nonspecific protein 
adsorption and inter-particle agglomeration increasing their circulation half-life in vivo [135]. 
(2) Gold NP delivering simultaneously Gd, photoacoustic and raman imaging agents have 
demonstrated picomolar sensitivity in the delineation of tumor margins both in vitro and in 
living mice. NP intravenous (i.v) injection into orthotopic glioblastome-bearing mice led to 
specific NP accumulation and retention by the tumors for an extended period of time allowing 
for non-invasive pre-and intraoperative tumor delineation using MRI, photoacustic and raman 
imaging through the intact skull [136]. (3) The use of Gd loaded liposomes administered by 
CED [137, 138] and (4) Gd loaded PAMAM dendrimers for MRI contrast enhancement have 
similarly been reported [139, 140]. 
Superparamagnetic iron oxide-NP (SPIO) are a novel T2 MRI contrast agent developed over 
the past decade that tend to persist longer in the brain parenchyma and delineate tumor 
margins more accurately than other contrast molecules [130]. The non-toxicity of 
biodegradable iron based-NP has also been demonstrated. The capacity for highly selective 
tumor targeting is a major advantage of iron oxide-NP over Gd. Ultrasmall superparamagnetic 
iron oxide (USPIO) are taken up by reactive phagocytic cells that are commonly found at 
infiltrating tumor margins [141] and long circulating dextran coated iron oxide NP are 
internalized by dividing tumor cells [142]. Iron-oxide NP surface allows chemical linkage of 
functional groups or ligands to improve diagnostic specificity. Thus, over the past few years, 
iron oxide NP have been linked to specific brain tumor ligands for imaging. In this context, 
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amphiphilic blocked polymer coated iron oxide NP have been conjugated to EGFRvIII 
antibody present in human glioblastoma multiforme for MRI guided CED and targeted 
glioblastoma therapy [54]. Bioconjugated NP locally administered allowed MRI contrast 
enhancement in a mouse glioma model. Effective intratumoral and peritumoral distribution of 
NP in the brain together with a significant increase in animal survival were found after 
EGFRvIII–conjugated NP administration [54]. This study provides the proof that monoclonal 
antibodies conjugated to iron oxide NP may provide specific brain cancer diagnosis with the 
use of MRI. Chlorotoxin 4, a highly specific marker for glioma cells has also been attached to 
USPIO [143]. In this sense, Veishe et al. developed a multifunctional nanoprobe capable of 
targeting glioma cells detectable by both MRI and fluorescence microscopy. Iron oxide NP 
were coated with PEG and then functionalized with chlorotoxin and with the fluorescent 
molecule Cy5.5 [143]. This nanoprobe was further validated in a transgenic mouse model of 
human medulloblastoma, the most common malignant childhood brain tumor, demonstrating 
its ability to cross the BBB without causing BBB damage and specifically target brain tumors. 
MRI and NIRF imaging demonstrated NP specific targeting to tumors in vivo and validated 
the nanoprobe as MRI and optical contrast agent [144]. The peptide F3, a tumor specific 
peptide that binds to nucleolin overexpressed on proliferating tumor endothelial cells was 
conjugated to SPIO NP and i.v. administered to the rat 9L glioma model. F3-coated NP 
provide a significant magnetic resonance imaging contrast enhancement compared to non-
coated F3 NP [145].  
A different approach is proposed by Nie et al., who studied F3-targeted hydrogel NP with 
covalently linked coomasie blue for delineation of brain tumors [146]. The nanosystem 
allowed direct brain tumor visualization with no need for extra equipment or special lighting 
conditions.  
2.2 Nanotechnology for improving AD diagnosis 
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Alzheimer disease (AD) is the leading cause of dementia worldwide. It is estimated that more 
than 35 million people worldwide have AD [155]. The loss of memory and other cognitive 
domains cause death within 3 to 9 years after diagnosis. The pathological hallmarks include 
two distinct types of protein aggregates: the extracellular amyloid-β (Aβ) plaque and the 
intracellular hyperphosphorylated tau neurofibrillar tangles [155]. Both aggregates are 
neurotoxic and can produce cognitive impairment. The pathological changes are accompanied 
by increased oxidative stress, elevated metal ion levels and a widespread degeneration of 
cholinergic neurons in the cortex, hippocampus, basal forebrain and ventral striatum, which 
results in lower acetylcholine (ACH) levels and a reduction of cholinergic transmission of 
cortical neurons in the brain [155]. The diagnostic guidelines of AD include brain imaging 
and cerebral fluid biomarkers. Although blood is more accessible than cerebral fluid, protein 
concentration in the blood is lower making the detection more difficult to perform. Ideally, 
biomarkers may provide means of early AD detection that is very interesting for disease 
modifying treatments. In addition, biomarkers may be preferably stage-specific. Current 
biomarkers include phosphorylated tau indicating the tangle pathology, total tau amount that 
correlates with neuro-axonal degeneration, and the 42 amino acid Aβ isoform (Aβ42) which 
correlates inversely with plaque pathology [156]. Recently, amyloid-derived diffusible 
ligands (ADDLs) have been proposed as early AD indicators [157]. 
Nanotechnology appears to be a useful and promising tool in AD diagnosis (reviewed in 
Brambilla et al. [158]). Nanotechnology may improve the analytical sensitivity of both 
imaging and cerebral fluid biomarkers. This may result in early disease detection leading to 
less costly therapeutic demands and improved clinical results. Remarkably, many of the 
examples described below have not been validated in vivo. Hence, attention should be paid to 
the potential toxicity of nano-based diagnostic medicines.  
2.2.1 Brain imaging biomarkers based on nanotechnology 
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The use of iron oxide NP as MRI contrast agents has been extensively investigated The most 
frequent iron oxide NP conjugated to Aβ peptide for amyloid plaque detection are 
monocrystalline iron oxide NP (MIONs) [151], small SPIONP [159] and USPIONP [152]. 
The main inconvenience of these biomarkers is that they detect Aβ plaque that is observed in 
later more advanced stages of the disease. Thus, the technique would not be useful for very 
early AD diagnosis. More innovative is the approach of Skaat et al., who prepare a hybrid 
system that combines magnetic and fluorescence imaging into one nanostructure system. For 
that purpose, the authors prepare fluorescent magnetic γFe2O3-rhodamine and γFe2O3-congo 
red NP. The system might enable early detection using both MRI and fluorescence 
microscopy and plaque removal using a magnetic field [160]. Only in vitro studies have been 
published with this technology until now. 
Thioflavin T selectively recognizes B-sheet structures of Aβ both in vitro and in vivo. 
However, thioflavin T is unable to cross the BBB. Siegemund reported that Aβ can be 
selectively targeted by Thioflavin T after its release from core-shell polystyrene polysorbate-
80 PBCA NP. Aβ deposits in the hippocampus were observed by fluorescent microscopy in 
transgenic mice with age-dependent β-amyloidosis after thioflavin T loaded NP 
intrahippocampal injection [161]. No targeting of Aβ was observed after iv infusion of the 
particles. 
Choi et al. described the use of a novel contrast agent based on gold NP to improve the MRI 
sensitivity. A cobalt (II) magnetic core and a platinum shell directly fused onto gold NP and 
stabilized by a coating of lipoic acid-PEG were prepared. The terminal carboxyl groups of the 
PEG chains allowed covalent binding with neutravidin lysine residues at the NP surface. NP 
were used together with MRI to monitor Aβ assemblies structural evolution, especially Aβ 
protofibrils in the early reversible stages [162].  
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Quantum dots (QD) are nanoscale semiconductor crystals with special fluorescent properties. 
However, possible health hazards associated with the use of semiconductor materials have 
limited their general application. In order to reduce toxicity, some authors have encapsulated 
QD in polymers or have coated them with PEG. Tokuraku et al. developed PEG-coated QD-
crosslinked with Aβ peptide able to examine Aβ fibril oligomer formation in vitro and in an 
intact cell system. Remarkably, QD-Aβ nanoprobes successfully pass through the BBB [163]. 
Recently it was reported that transferrine conjugated QD-Aβ were able to traverse through an 
in vitro BBB model via receptor mediated transport [164]. 
Härtig labeled hippocampal Aβ with the fluorescent acetylcholinesterase inhibitor PE154 
released from two types of NP, carboxylated polyglycidylmethacrylate NP and polystyrene-
PBCA NP, in triple transgenic mice. Targeting of Aβ, but not phospho-tau, by PE154 was 
shown by confocal-laser scanning after NP intrahippocampal injection [165]. 
2.2.2 Fluid biomarkers based on nanotechnology 
Georganopoulou et al. have demonstrated that bio-barcode assays based on DNA-NP 
conjugates are capable of measuring subfemtomolar concentration of ADDL level in CSF. 
The bio-barcode assay is a ultrasensitive diagnostic tool used for the enzyme-free detection of 
proteins and nucleic acids. In the case of proteins they are 106 times more sensitive than 
ELISA because carrier gold NP match the specific antibody of the target biomarker with 
hundreds of DNA barcodes [166]. 
Noble metal NP, such as silver or gold NP, have been explored to develop ultrasensitive fluid 
biomarkers for AD. For instance, a nanosensor based on silver NP optical properties to detect 
low ADDL concentration in CSF using localized surface plasmon resonance (SPR) was 
developed. Modifications in the NP external environment produce changes in the surrounding 
magnetic field refractive index that result in variations in the silver NP λ max detectable via 
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spectroscopy. Since the solution concentration directly changes the refractive index, the 
biosensor is sensitive to different ADDL concentrations [167, 168]. 
Regarding bioassays using gold NP, Chikae et al. proposed an electrochemical Aβ sensor 
based on saccharide-protein interactions whose detection sensitivity was improved by 
immobilizing the saccharide sialic acid on gold NP. The detection of Aβ peptide down to 
submicromolar concentration was demonstrated [169]. Lee et al. used an ultrasensitive 
immunosensor for Aβ (1-40) detection based on SPR. Gold nanoparticle functionalized with 
an antibody fragment able to specifically recognize Aβ was used as a way to enhance SPR 
detection [170]. The immunosensor developed proved to be highly sensitive in the detection 
of Aβ and enhanced the detection limit from 10 ng/mL to 1 fg/mL compared to a bare gold 
substrate. Another approach was the development of an electrical method for Aβ 
immunodetection based on gold NP using scanning tunneling microscopy (STM). The vertical 
detection immunoassay that comprises corresponding antibody fragments, Aβ, and gold NP-
antibody conjugates was combined with STM for electrical detection. The current proposed 
method successfully detected 1 fg/mL of Aβ [171]. It is also possible to use a Rayleigh 
scattering assay based on gold NP coated with a monoclonal antibody against tau for the 
selective detection of tau protein at a concentration of 1 pg/mL. The two-photon Rayleigh 
scattering assay showed a strong sensitivity for tau protein. It was able to discriminate other 
proteins such as bovine serum albumin which is one of the most abundant protein components 
in CSF [172]. 
2.3 Nanotechnology for improving PD diagnosis 
PD is a complex and heterogeneous neurodegenerative disease characterized by the 
progressive nigrostriatal dopaminergic system degeneration, which causes DA loss in the 
brain. This disease affects approximately 5 million people globally and its etiology is still 
unknown [173]. Clinically, it is characterized by four motor symptoms that are bradykinesia, 
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resting tremor, rigidity and a marked difficulty to perform coordinated movements. It is 
generally accepted that Parkinsonian motor signs appear when 70–80% of striatal 
dopaminergic nerve terminals and 50–60% of substantia nigra compacta dopaminergic 
neurons are death [174]. Regarding PD diagnosis, there is an urgent need for biomarkers, 
preferably at early premotor stages when neuroprotective drugs have been shown to slow 
disease progression. However, there is no validated, reliable, inexpensive and simple biofluid 
or imaging marker available yet [175]. A promising potential premotor biomarker recently 
proposed by Shannon et al. is α-synuclein pathology in the colon [176]. However, its 
sensitivity and specificity have not been established yet for a reliable cost-effective paradigm. 
In this context, nanotechnology could be particularly useful. Other novel nanotechnological 
approaches to diagnose PD include the work of Baron et al., who described the use of a 
colorimetric assay to detect DA, L-DA, noradrenaline, adrenaline and tyrosinase activity 
based on the growth of Au-NP induced by the neurotransmitters and detected by plasmon 
absorbance [177]. 
Aptamers are functional nucleic acid sequences able to bind specific targets. Nanoparticle-
aptamer bioconjugates have been recently used for targeted delivery and diagnosis of several 
cancers. An aptamer with a high specificity and binding affinity for α-synuclein could be used 
to test α-synuclein levels in the blood of patients with PD. With this idea, Tsukakoshi et al. 
reported the identification of DNA aptamers that bind to soluble α-synuclein oligomers. A 
competitive screening method based on aptamer blotting was used to isolate 8 DNA aptamers 
that specifically bind to α-synuclein oligomers [178]. 
Concerning the use of nanotechnology for in vivo PD diagnosis few data are available. 
Especially remarkable is the work of Tisch et al. who detect asymptomatic nigrostriatal 
dopaminergic lesion in rats using carbon nanotube sensors to analyze exhaled air. This 
approach relies on the principle that the volatile organic compound pattern is different in the 
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exhaled breath of healthy and PD patients. Changes were observed in the chemical 
composition of the breath samples from 6-OHDA-lesioned rats and sham-treated animals, 
which led to the sensor-array breath-print. This study demonstrates that breath testing could 
improve neurodegenerative disease early detection [179]. 
3 NANOMEDICINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS 
3.1 Nanotechnololgy for brain tumor treatment 
Malignant gliomas are generally treated with a combination of surgery, radiotherapy and 
systemic chemotherapy [180, 181] and metastatic brain tumors with a combination of surgery 
and radiotherapy [126, 182-185]. However, patient median survival times are low [127, 186, 
187]. The point has already been made that the ineffectiveness of chemotherapeutic drugs in 
treating brain tumors is mainly ascribed to the BBB, which hampers the delivery of the drugs 
to the extravascular compartment of the tumor. However, it has been shown that when the 
tumor cell cluster reached a volume large enough (> 0.2 mm3) the BBB will be damaged and 
the blood-brain tumor barrier (BBTB) will be formed [128]. This BBTB exists between the 
brain tumor tissues and capillary vessels and prevents the delivery of most hydrophilic 
molecules and antitumor agents to brain tumor [188]. In contrast to this, it has also been 
observed that BBB could remain intact in the case of infiltrative gliomas or micrometastases 
[189]. Brain tumor neovasculature is functionally different from both normal brain capillaries 
and the neovasculature of peripheral tumors. In this case, the gap size in the vascular 
endothelium of the BBB was found to be up to 600 nm in diameter, [190, 191] while the size 
of those that can be found in brain tumors is significantly smaller (≈12 nm) [190]. 
Researchers have taken this characteristic into account in the design of brain-tumor targeting 
nanostructured carriers with smaller diameters that can access the brain tumor through these 
12 nm gaps, but are not able to extravasate across the normal BBB [192]. Even though 
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treating tumors in the CNS is difficult, the development of nanotechnological drug delivery 
systems can play importantroles in overcoming the hurdles of current therapies against brain 
tumors. These nanomaterials can be formulated with chemotherapeutic drugs to produce drug-
polymer assemblies that can beinjected or implanted and, as a result, allow a localized and 
sustained delivery of the entrapped drug [114]. 
3.1.1 Non-invasive approaches  
One of the clearest advantages of systemic drug delivery is its non-invasive nature. 
Nevertheless, in order to achieve therapeutic concentrations in the brain, larger systemic drug 
doses would be required. In this case, the properties of nanomaterials may offer solutions to 
this drawback. The best treatment for brain tumor-targeted drug delivery should be able to 
transport the therapeutic agents at the brain tumor foci minimizing the involvement of healthy 
brain tissue as well as of peripheral tissues [115, 193]. 
A) Polymeric nanoparticles 
Polymeric NP are probably the most widely used DDS to deliver chemotherapeutic drugs to 
the brain (Table 2) and Tf is one of the most frequently studied receptors for the targeting of 
nanomedicines by receptor mediated transcytosis, because of its high expression on the BBB 
[194, 195]. For instance, Liu et al. conjugated Tf to the surface of doxorubicin loaded PEG-
PLA NP to specifically target the NP to glioma. They observed that intravenously 
administered NP could deliver doxorubicin into the tumor sites, leading to a reduction of the 
tumor growth and prolonged survival of the animals, compared to controls [196]. Cui et al. 
designed a Tf-conjugated magnetic silica PLGA NP loaded with doxorubicin and paclitaxel to 
overcome the BBB. After their iv administration, these NP exhibited the strongest anti-glioma 
activity as compared to the control formulations [197]. Similar or even better anti-tumor 
effects were obtained by Wohlfart et al., with doxorubicin bound to PLGA NP coated with 
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poloxamer 188 [198]. Increased brain tumor concentrations also were observed with 
polysorbate 80-coated PBCA NP loaded with temozolomide, methotrexate or doxorubicin 
after their i.v. injection to rats [122, 199-201]. Wang et al. investigated the anti-tumor activity 
of gemcitabine bound to the polysorbate 80-coated PBCA NP in rats after C6 glioblastoma 
implantation into the brain [202]. They observed a 20% increase in medium survival time 
from day 21 to 25. In another study by Xin et al., paclitaxel loaded into mPEG-PCL NP was 
intravenously administered to C6 glioblastoma bearing mice [203]. The mean survival times 
with this formulation increased by 40% compared to a paclitaxel administration and by 20% 
compared to non-PEGylated NP.  
Polymeric materials can be used to deliver nucleic acids such as oligonucleotides, but often 
have low efficacy in human cells. However, while the simple attachment to NP alone results 
only in a slight improvement of intracerebral uptake of oligonucleotides, an additional coating 
with polysorbate 80 can lead to a 20-fold higher amount of cellular uptake in an in vitro 
model of the BBB [204, 205]. This was observed by Schneider et al., who concluded that 
polysorbate 80 coated NP provide a non-viral method of gene delivery to brain cells and brain 
tumors [206]. Lu et al. achieved a significantly delayed tumor growth and induced apoptosis 
in vivo after repeated i.v. injections of cationic albumin-conjugated pegylated NP loaded with 
plasmid pORF-hTRAIL as a nonviral vector for gene therapy of gliomas [207]. 
B) Lipid nanoparticles 
Many studies have been performed in order to deliver chemotherapeutic drugs to the brain by 
means of lipid nanoparticles (Table 3). In vivo studies in rats by Martins et al. showed that 
fluorescently labeled SLN containing camptothecin were detected in the brain after i.v. 
administration [228]. Our group observed that there was an increased amount of drug in brain 
tissue when the antitumor lipid edelfosine loaded into lipid nanoparticles was orally 
administered, compared to the drug solution [121]. However, there are still few efficacy 
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studies performed in vivo. Jin et al. proved that the i.v. administration of c-Met siRNA-
PEG/cationic SLN complex in orthotopic U-87MG xenograft tumor model significantly 
inhibited c-Met expression at the tumor tissue and suppressed tumor growth without showing 
any systemic toxicity in mice [229]. Huynh et al. observed that the treatment with DSPE-
mPEG2000-FcdiOH-LNCs and FcdiOH-LNCs statistically improved median survival time 
(28 and 27.5 days, respectively) compared to the control (25 days) in a 9L intracranial 
gliosarcoma model. 
C) Liposomes 
Liposomes have also been used to deliver chemotherapeutic drugs to the brain (see Table 4). 
They have also been linked to Tf in order to achieve higher brain tumor delivery. For 
instance, Soni et al. conjugated Tf to the surface of liposomal vesicles to enhance the brain 
delivery of the anticancer drug 5-florouracil [240]. Biodistribution studies suggested a 
selective uptake of the Tf coupled liposomes from the brain capillary endothelial cells. 
Indeed, after the liposomal delivery of 5-fluorouracil researchers observed an average of 10-
fold increase in the brain uptake of the drug, while the TfR-coupled liposomes caused a 17-
fold increase in the brain uptake of 5-fluorouracil. In a similar way, Ying et al. attached Tf 
and aminophenyl-alpha-D-manno-pyranoside to the surface of their daunorubicin loaded 
liposomes to both target brain tumor tissue by the Tf and cross the BBB, due to the specific 
binding of the pyranoside molecule to the GLUT1 receptor in the BBB. They observed that 
the median survival time of tumor bearing rats after administering these targeted liposomes 
was significantly longer than that after giving free daunorubicin [241]. Topotecan and 
tamoxifen have been also delivered to the brain loaded into liposomes showing WGA on their 
surface. Du et al. showed that tamoxifen could inhibit the efflux of MDR proteins in the BBB, 
while the WGA would enhance the endocytosis of the liposomes in the BBB and in the brain 
tumor, correlating with an increased efficacy of the nanosystem [242]. 
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D) Dendrimers 
The branched architecture of dendrimers is an attractive feature for targeted delivery 
applications, as they can present targeting ligands in a manner favorable to promote 
multivalent binding to target brain receptors and eventually cross the BBB [252]. The most 
representative examples of drugs administered using dendrimers for brain tumor treatment are 
included in Table 5. Interferon beta was successfully linked to arginine surface modified 
PAMAM dendrimers. In this study, Bai et al. observed that U87MG tumor bearing mice 
treated with PAMAM-R/pORF-IFN-beta exhibited a significantly smaller tumor size than 
control mice and PAMAM-R/pORF treated mice [253]. In another experiment, Huang et al. 
suggested that chlorotoxin (CTX) could be exploited as a special glioma-targeting ligand, as 
PAMAM–PEG–CTX/DNA NP showed high gene delivery in a mouse glioma model via i.v. 
administration [254].  
The cell adhesion molecule integrin αvβ3 plays an important role in cancer progression and is 
overexpressed in melanomas, glioblastoma, ovarian, breast, and prostate cancers. The Arg-
Gly-Asp (RGD) containing peptides have been identified to have high affinity with integrin 
αvβ3 [255]. Zhang et al. observed that their RGD modified doxorubicin loaded PEG-PAMAM 
conjugates were able to increase the median survival time up to 50 days, compared to the 14 
days achieved with the free doxorubicin [256]. 
E) Carbon nanotubes 
So far there are few studies that show the efficacy of these nanomaterials in vivo. Ren et al. 
investigated the feasibility of Angiopep-2 linked PEGylated oxidized multi-walled CNT 
containing doxorubicin for the treatment of brain glioma in glioma bearing mice [110]. These 
nanosystems significantly prolonged mean survival time compared to the administration of 
saline or free doxorubicin. 
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3.1.2 Invasive approaches; local administration 
Among the treatment approaches that were previously described, it seems that direct injection 
of therapeutic agents into the brain after tumor resection is not always the best option in brain 
cancer treatment, as the diffusion coefficient of compounds is rather limited [259]. As a 
result, new anticancer drug formulations should be developed in order to be useful for brain 
tumor treatment by direct injection in the CNS as this provides a higher drug concentration at 
the tumor site while systemic toxicity is decreased [114]. As we have already discussed, 
strategies for local drug delivery include intraventricular, intraparenchymal or intratecal 
delivery of the agent, the CED and locally implanted systems, all of which are invasive. 
However, the most significant advantage of all these systems is that they directly bypass the 
BBB, increasing the bioavailability of the therapeutic agent in the CNS [260]. Illustrative 
examples are included in Table 2, 4 and 5. 
A) Polymeric nanoparticles 
Few studies can be found for local delivery of polymeric nanomedicines to treat brain tumors 
(see Table 2). Polymeric micelles composed of polyaspartic acid and PEG have been used to 
deliver doxorubicin by CED to xenograft gliomas in rats, resulting in significantly longer 
survival rates of animals compared to the free drug [214]. Temozolomide was also 
incorporated into polymeric nanoparticles along with an MRI agent in order to obtain a 
multifunctional platform that can be used for image-guided treatment of malignant glioma 
[50]. PLGA has also been widely employed for brain DDS preparation. Sawyer et al. 
observed that camptothecin loaded PLGA NP stereotactically delivered by CED improved 
survival in rats with intracranial 9L tumors: the median survival for rats treated with these NP 
was significantly longer than that of unloaded NP and free camptothecin infusion [209]. 
B) Liposomes 
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In order to favor the association and interaction with the brain, liposome size, charge and 
surface properties can be easily modified by adding new components to the lipid mixture 
before liposome preparation, by varying liposome preparation methods or by selecting the 
appropriate administration route [261]. For instance, Chen et al. observed a significantly 
greater anti-tumor activity and survival benefit from CED of irinotecan-loaded liposomes, 
compared to the systemic administration of the same liposomes [55]. 
Monoclonal antibodies could also act as a “molecular Trojan horse” and allow delivery 
systems to cross BBB. MAb-conjugated liposomes, also known as immunoliposomes, have 
proved effective as brain drug delivery systems [262]. For instance, Zhang et al. developed 
immunoliposomes, carrying a plasmid DNA encoding the EGF receptor antisense mRNA, 
conjugated with two monoclonal antibodies directed to mouse Tf receptor, in order to get 
through the BBB, and to human insulin receptor for intratumor cell delivery [263]. This study 
showed that these immunoliposomes are effective after i.v. administration in mice bearing 
U87 brain tumors. Similarly, Gosk et al. observed that when OX26 monoclonal antibody was 
coupled to daunomycin containing PEG-immunoliposomes, the accumulation of drug was 
increased in the brain tissue after i.v. administration, compared to the PEG-liposomes without 
the monoclonal antibody [264]. 
C) Dendrimers 
In the last few decades, various PAMAM-based drug carriers have been developed to 
investigate their potential use for cancer therapy (Table 5). Even though PAMAM dendrimers 
have shown potential as DDS in brain tumor cell lines in vitro, [265-269] so far the reports of 
dendrimers applied to brain tumor targeting and therapy in vivo are still limited and still need 
to be optimized [252]. Yang et al. studied the feasibility of using boronated PAMAM 
dendrimers with EGF as targeting moiety for the treatment of gliomas. They observed that the 
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CED of the EGF bound dendrimer was therapeutically more effective than the intratumor 
injection of the same nanosystem [258]. 
Nevertheless, we have to take into account that local delivery methods showed some 
limitations. The exponential decrease of the drug diffusion from the implanted nanostructure 
as the distance from resection cavity increases and the limitation of drug dosage by the size of 
the implant are two significant examples of these drawbacks [270]. These facts reduce the 
therapeutic drug concentration in cells that are a few centimeters away from the implant, 
presenting high risk of local neurotoxicity, cerebral edema or infection. Furthermore, the use 
of these invasive techniques requires the hospitalization of the patient and the need for highly 
experienced personnel in order to apply anesthesia for the local implantation of devices [260]. 
3.2. Nanotechnology for AD therapy 
While there is no cure for AD, cholinesterase inhibitors are approved by the FDA to treat its 
symptoms and are so far the most effective therapeutic approach. These drugs provide 
symptomatic short-term relief without affecting disease progression, though a neuroprotective 
potential has also been proposed (revised in Salomone et al.[271]). Results reviewed by 
Salomone et al. demonstrate that there is an urgent need to develop disease modifying 
treatments able to counteract the progression of AD since none of the current available 
strategies have demonstrated efficacy in phase III clinical trials. Advances in 
nanotechnologies hold great promise to exert a significant impact on AD treatment. The most 
thoroughly investigated nanotechnology-based approaches have been directed to combat 
amyloid cluster toxicity enhancing their clearance or modifying their aggregation kinetics in 
the brain or in the blood with the idea of reducing their brain levels (the so-called “sink 
effect”). Other strategies have been focused on the encapsulation of several drugs with anti-
oxidant, neuroprotectant or cholinesterase inhibitor properties into NP for their targeted 
delivery to the brain (reviewed in Garbayo et al.[61] and in Brambilla et al.[158]). Although 
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promising, these findings should be considered preliminary since few of them have 
demonstrated their efficacy using in vivo AD models or in clinical practice. 
3.2.1 In vitro studies 
A) Nanoparticle-mediated protein aggregation manipulation  
Curcumin, a bioactive component of the golden spice turmeric (Curcuma longa), has anti-
amyloid aggregation, anti-tau hyperphosphorylation, anti-oxidant and anti-inflammatory 
properties. However, it shows poor bioavailability due to its instability, low solubility and 
rapid metabolism. Mathew et al, evaluated the anti-amyloid and anti-oxidant properties of 
curcumin PLGA NP conjugated with a targeting moiety-Tet 1 peptide and their in vitro 
uptake by GI-1 glioma cells showing that they can be a potential tool to treat AD. Tet-1 
peptide, which has affinity to neurons and possesses retrograde transportation properties, was 
effective in neuronal targeting. In addition, NP were able to destroy amyloid aggregates and 
showed free-radical scavenging activity and no cytotoxicity in vitro [272]. 
Markedly elevated zinc, copper and iron concentrations in amyloid deposits on the human AD 
brain are well documented in the literature [273]. Thus, chelating agents provide another 
tactic to reverse Aβ plaque formation. In this regard, the copper chelator D-penicillamine 
covalently conjugated to lipidic particles was able to dissolve pre-existing Aβ aggregates in 
vitro [274]. Further studies are needed to evaluate its in vivo efficacy and to demonstrate that 
this strategy is a viable alternative to traditional chelating agents.  
Another strategy to reduce protein aggregation is the use of gold NP. Recently, Hiesh et al. 
explored the gold NP inhibitory effect on the fibrillogenesis process of insulin fibrils 
demonstrating that when gold NP were co-incubated with insulin, an amyloidogenic protein 
model, the structural transformation into amyloid-like fibrils was delayed about a week in 
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vitro [275]. Similarly, Liao et al. overall showed that negatively charged gold NP inhibited 
Aβ-fibrillization [276]. 
Gobbi et al. prepared and characterized liposomes and SLN functionalized with the 
amphipathic lipid dimyristoylphosphatidic acid that showed high in vitro affinity for Aβ 
peptide. The ability of the lipid-based nanosystems to bind the peptide was assessed in vitro 
by using SPR technology. These nanovectors are very promising for the targeted delivery of 
diagnostic and therapeutic molecules [277]. 
Particularly innovative is the use of biocompatible poly-aminoacid-based polymer NP 
containing hydrophobic dipeptides in the polymer side chains, proposed very recently by 
Skaat et al., to inhibit Aβ-aggregation. Two dipeptide residues were designed similarly to the 
hydrophobic core sequence of Aβ and included in the polymer side chains for NP preparation. 
Thus poly(N-acryloyl-L-phenylalanyl-L-phenylalanine methyl ester) (polyA-FF-ME) NP and 
poly(N-acryloyl- L-alanyl-L-alanine methyl ester) (polyA-AA-ME) were synthetized and 
characterized. A significant inhibition of the Aβ40 fibrillation process in vitro in the presence 
of these NP was observed together with no significant toxicity on different cell lines [278] 
B) Nanogel-assisted protein refolding 
Several authors have investigated the potential application of biocompatible nanogels as 
artificial chaperones for controlling Aβ fibril aggregation and cytotoxicity. In this view, Ikeda 
et al. demonstrated that biocompatible cholesterol-bearing pullulan (CHP) nanogels inhibited 
amyloid fibrin from forming and released monomeric Aβ molecules on addition of methyl-β-
cyclodextrine [279]. CHP nanogels prevented AB oligomerization and protected PC12 and 
primary cortical and microglial cells from Aβ neurotoxicity [279-281]. CHP nanogels could 
be a valid approach to treat AD, but further experiments demonstrating in vivo BBB surpass 
and efficacy are required. 
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C) Nanoliposomes with high affinity for amyloid β peptide. 
Mourtas et al. prepared two types of nanoliposomes functionalized with curcumin derivatives 
with high affinity for Aβ peptide by a conventional synthetic method or with a click chemistry 
method. Curcumin-decorated nanoliposomes prepared with the click chemistry showed the 
highest affinity for Aβ fibrils reported to date and sufficient integrity and stability for in vivo 
applications [282]. Taylor et al., who studied the effect of nanoliposomes associated with 
different ligands on Aβ aggregation obtained similar results. Ligands evaluated were 
curcumin, phosphatidic acid, cardiolipin, or GM1 ganglioside, the click-curcumin type being 
by far the most effective [283]. Unfortunately, no in vivo experiments have been performed. 
D) PEGylated nanomicelles that inhibit protein aggregation 
Pai et al. proposed for the first time the potential use of PEGylated phospholipid nanomicelles 
as therapeutic agents against AD. The work demonstrated that nanomicelles were effective in 
mitigating the Aβ capacity to aggregate into plaques and to moderate its in vitro neurotoxicity 
using the human neuroblastoma cell line SHSY-5Y [284]. If further in vivo studies confirm 
these results, the authors suggest that PEGylated phospholipid nanomicelles could be 
effective to slow down AD progression since they mitigate Aβ aggregation by 
accommodating Aβ molecules in α-helical conformation that results in reduced aggregation 
and amyloidogenicity [284]. 
E) Nanoparticles for cholinesterase inhibitors 
Pagar explored a novel L-lactide-depsipeptide copolymer for rivastigmine-loaded polymeric 
NP preparation. The effects of excipients and formulation variables on the NP were analyzed 
in detail [285]. More recently, Luppi et al, investigated intranasal formulations of tacrine 
based on albumin NP carrying different cyclodextrins and some of their hydrophilic 
derivatives. NP carrying cyclodextrins showed mucoadhesion in vitro and ex-vivo and in 
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particular HP-β cyclodextrin showed the highest mucoadhesive properties. Intranasal 
absorption studies in AD animal models are now needed to further validate this strategy 
[286]. 
F) Carbon nanotubes for acetylcholine administration 
Yang et al. proposed for the first time the use of CNT as drug carriers for the treatment of 
CNS diseases [287]. CNT are able to enter the brain via nerve axons. Single-walled CNT 
were loaded with ACH and their efficacy and toxicological profile after oral administration 
were examined in an experimentally-induced mouse AD model. Since CNT have generated 
serious concerns about their safety profile, toxicological experiments were of great 
importance to address whether CNT could be used as drug carriers. CNT successfully 
delivered ACH to the brain and improved learning and memory capabilities whereas free 
ACH or CNT alone did not elicit any effect. These positive effects showed good dose-effect 
relation. Regarding toxicity, CNT were highly safe at low doses and only high doses caused 
pathological changes in the ultrastructure of mitochondria and lysosomes [287]. Since not 
much is known regarding chronic CNT toxicity, further experiments are required to 
address/elucidate the possible health risk and hazards.  
3.2.2 Non invasive approaches 
Examples of nanomedicines for AD treatment already tested in vivo are provided in Tables 2, 
3 and 4.  
A) Nanoparticle-mediated protein aggregation manipulation 
Chen et al. tested the efficacy of curcumin PEG-PLGA-polyvinylpyrrolidone NP freeze dried 
with β-cyclodextrin orally administered in AD Tg2576 mice [210]. Curcumin nanovector-
treated animals showed significantly better cue memory in the contextual fear conditioning 
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test compared to placebo, and better working memory in the contextual fear maze test than 
with free curcumin and placebo after a three-month-treatment [210]. 
B) Nanoparticle-mediated neuroprotection 
Quercetin, a natural flavonoid with antioxidant activity, was nanoencapsulated into 
polysorbate 80-coated solid lipid NP and intravenously administered in rats with aluminium-
induced dementia [234]. Animals improved memory retention in the spatial navigation task 
and in the elevated plus maze paradigm compared to free quercetin administration. Moreover, 
quercetin-loaded NP significantly reversed the increase in malondialdehyde and nitrite levels 
and the depletion of reduced GSH induced by the aluminium chloride chronic administration 
demonstrating the potential of solid lipid NP as a platform technology. 
The octapeptide derived from the activity-dependent neuroprotective protein (NAP) is a 
promising neuroprotective agent for AD. In order to enhance its brain delivery and to protect 
the neuropeptide from degradation, Liu et al. proposed its nanoencapsulation in B6 peptide-
modified PEG-PLGA NP [219]. In vivo biodistribution experiments after i.v. administration 
of the nanovector through the tail vein demonstrated that B6 peptide mediated brain targeting 
and allowed a higher NP brain accumulation. B6-NP-NAP significantly ameliorated the loss 
of hippocampal neurons, the spatial learning deficit and the cholinergic dysfunction in mice 
stereotaxically coinjected with Aβ-1-40 and ibotenic acid. 
C) Nanoparticles for cholinesterase inhibitors 
Rivastigmine, an established non-competitive and reversible cholinesterase inhibitor, 
improves or maintains cognitive function, global function and behavior in patients with AD. 
However, its oral therapy includes limited entry into the brain due to its hydrophobicity, 
frequent administration and cholinergic side effects. With the idea of improving rivastigmine 
treatment, Wilson prepared polysorbate 80 PBCA NP and investigated if they enable the 
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transport of rivastigmine across the BBB and the effect of polysorbate 80 on drug brain 
delivery. Biodistribution studies after i.v. NP administration in rats demonstrated a 3.8 fold 
increase in rivastigmine brain uptake compared to free drug [221]. Apo E adsorbed from the 
blood to the particle surface after i.v. administration mediates NP internalization through BBB 
low-density lipoprotein receptors. Similar results were obtained by the same author when 
using chitosan polysorbate 80 coated NP [222]. In another study, Joshi et al. reported memory 
improvement in scopolamine-induced amnesic mice after treatment with PLGA or 
polysorbate 80-PBCA rivastigmine loaded NP [223]. Piperine has shown significant anti-
acetylcholinesterase activity. However this drug has first pass-effect and high doses are 
required to exert its neuropharmacological effect. In order to overcome this limitation piperine 
NP could be prepared. Yusuf et al. studied the therapeutic effect of polysorbate 80 coated 
lipid NP encapsulating piperine intraperitoneally administered in an experimentally induced 
AD model in rats [235]. Piperine delivered by SLN at a dose 2.5-fold lower than the control 
donepezil reduced the amyloidal content and tangles of the nucleus basalis magnocellularis 
through reduced oxidative stress and cholinergic degradation [235]. 
Tacrine is another cholinesterase inhibitor with potential significance in AD. With the idea of 
increasing tacrine brain delivery and to reduce its side effects Wilson et al., prepared 
polysorbate 80-coated PBCA NP and polysorbate 80-coated chitosan NP and studied NP 
biodistribution in rats after its i.v. application into the tail vein [224, 225]. The polysorbate 80 
significantly increases tacrine uptake into the brain in comparison with the free drug alone 
and the drug bound to NP for both formulations confirming the specific role of polysorbate 80 
in brain targeting. 
Md S et al. showed a high concentration of donepezil in brain after i.v. administration of the 
drug nanoencapulated in PLGA NP. Biodistribution studies using gamma scintigraphy 
techniques revealed a significantly higher percentage of NP formulation in the brain as 
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compared with the drug solution, demonstrating the potential of the nanosystem to enhance 
drug delivery to the brain [212]. 
Especially remarkable are very recent studies from Zhang et al., which reported dual-
functional NP based on a PEGylated PLA polymer targeting amyloid plaques in AD mice 
brains [288]. Two targeting peptides were conjugated to the NP surface: one specifically 
targets ligands at the BBB while the other has good affinity for Aβ. Brain distribution studies 
in mice and ex-vivo imaging confirmed that dual-functional NP achieved enhanced and 
precise Aβ targeting in vitro and in vivo. In addition, no cytotoxicity in PC12 cells and bEnd 3 
cells was found after 24 h of treatment with the particles. Ideally, multiple target NP will 
allow for better specifity and selectivity, thereby reducing the needed drug dose, as well as the 
potential harmful side effects [288]. 
 D) Liposomes for cholinesterase inhibitors 
Liposomes have been investigated to deliver rivastigmine to the CNS via the intranasal route 
[245]. The pharmacokinetic of the drug intranasally administered using liposomes in rat 
plasma and brain was studied. Significantly greater levels of rivastigmine were found in the 
brain compared to the administration of the free drug through the intranasal route or orally 
administered. No efficacy studies in AD models have so far been reported using this delivery 
system [245]. 
 E) Liposomes for antioxidants 
Huang et al. investigated if the oral bioavailability and brain distribution of (+)-catechin could 
be improved using polysorbate-80 coated liposomes [243]. This drug improves brain atrophy 
and learning memory functions and ameliorates PD and AD progression [289]. However, its 
oral bioavailability is low. In vitro studies demonstrated that (+)-catechin loaded liposomes 
remained stable in the presence of gastrointestinal fluids. A significant increase in (+)-
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catechin blood levels was observed 6 and 8 hours after the oral administration of the drug-
loaded liposomes in rats. Brain distribution studies showed higher levels of the drug in the 
cerebral cortex, hippocampus, striatum and thalamus [243]. Efficacy studies using AD animal 
models are needed to further validate this novel strategy. 
3.2.3 Invasive methods; local administration 
A) Nanoparticle-mediated neuroprotection 
Vascular endothelial growth factor (VEGF) is a growth factor implicated in angiogenesis with 
specific roles in axonal outgrowth and neuroprotection. Like other proteins, VEGF clinic 
application is hampered because of formulation and delivery problems. A novel 
nanotechnology-based strategy was recently proposed by Herran et al. to deliver VEGF 
locally to the brain [227] (see Table 2). In order to avoid adverse effects related to 
neurotrophic factor systemic administration, a local drug delivery approach was proposed to 
deliver VEGF to target areas. VEGF-loaded PLGA nanospheres improved behavioral deficits, 
decreased Aβ deposits and promoted angiogenesis when administered through minimally 
invasive craniotomy in double transgenic amyloid precursor/presenilin 1 mice [227]. 
3.3 Nanotechnology for PD therapy 
Current treatments for PD are largely aimed at addressing motor symptoms enhancing DA 
levels in the brain and far fewer are focused on alleviating non-motor symptoms or on 
modifying disease progression (Revised in Meissner et al. [290] and in Garbayo et al. [291]) 
Regarding symptomatic therapies, both levodopa (L-DOPA), which exhibits low oral 
bioavailability and very low brain uptake due to its high peripheral degradation, and DA 
agonists are currently used in the management of PD patients. However, both treatments do 
not stop or slow PD progression and can potentially cause long-term motor complications 
such as the “wearing-off” effect, the “on–off” phenomenon, and dyskinesias. Thus, although 
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DA replacement is efficacious in the early stage of the disease, new agents that can extend the 
length of the treatment or ideally reverse the degenerative process are needed. Concerning 
neuroprotective and neurorestaurative treatments for PD, most of them are based on the use of 
protein or peptides that are easily degraded by enzymatic and body fluids. Thus, brain 
administration of these molecules constitutes a challenge as well. Currently, various 
nanoscale systems are being explored to deliver all of these drugs to the brain (reviewed in 
Garbayo et al. [61, 291]) 
3.3.1 In vitro studies 
 A) Nanoparticles for antioxidants, dopamine and dopamine agonist delivery 
Carrol et al. encapsulated the antioxidant Tempol in PLGA NP conjugated with the TfR 
OX26 antibody to increase the delivery to the brain by bypassing the BBB. In vitro studies 
demonstrated that antibody addition increased NP uptake by primary neuronal cells and by 
RG2 rat glioma cells. Cell viability studies showed that Tempol-OX-NP were more effective 
in preventing cell death by resveratrol in RG2 cells than Tempol-NP or than the free drug in 
solution [292]. 
An innovative multifunctional nanoplatform with both imaging and therapeutic purposes was 
proposed by Malvindi et al. Highly fluorescent quantum dots were functionalized with 2 
biomolecules: (1) succinyl DA which can be hydrolyzed by the enzymes cellular esterase to 
release the prodrug within the cells and (2) a galactose shell that can be recognized by the 
transporters of GLUT-1. Human nasopharyngeal epidermal carcinoma (KB) cells 
overexpressing the GLUT transported internalized the nanosystem through GLUT-1 on the 
outer cellular membrane. MTT cytotoxicity assay showed that the galactose core shell 
enhanced NP biocompatibility in comparison with the original nanocrystals [293]. 
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The dopamine agonist ropinirole shows hepatic first pass metabolism. With the aim of 
impoving its therapeutic efficacy in PD Patil et al., prepared ropinirole loaded-PLGA NP 
whose surface was engineered using vitamin E for naso-brain delivery of the drug [294]. The 
nanovector showed good retention of the formulation with no signs of damage on nasal 
mucosa.  
3.3.2 Non invasive approaches 
Currently available nanotechnology tools for PD treatment tested in vivo are included in Table 
2, 3, and 4. 
A) Nanoparticles for dopamine replacement 
Chitosan-based NP are currently one of the most widely studied nanosystems for PD. A 
vehicle for DA delivery based on chitosan NP was prepared by De Giglio et al. Quartz cristal 
microbalance with dissipation monitoring (QCM-D) and X-ray photoelectron spectroscopy 
showed a predominant location of DA on NP surface suggesting a rapid availability of the 
neurotransmitter in the brain [295]. Evaluation of the toxic effect of DA-NP and the free 
neurotransmitter on the in vitro BBB model MDCKII-MDR1 cell line, fthrough MTT assay 
showed that DA-NP were less toxic than the neurotransmitter after 3 hours of incubation. 
Measurement of oxygen reactive species suggested low neurotoxicity of DA-NP. Transport 
studies using the same cell line showed an improvement in DA transport through the in vitro 
BBB model using the nanovector. In vivo microdialysis studies in rats with intraperitoneal 
DA-NP injection demonstrated that the nanosystem was able to transport the neurotransmitter 
through the brain. In addition, it was observed a dose-and time-dependent striatal DA level 
increase [213]. Chitosan NP have also been used to encapsulate L-DOPA [218]. NP were 
combined with a thermo-reversible gel of pluronic for intranasal delivery. Chitosan NP 
suspension in saline elicited higher L-DOPA brain levels compared to NP dispersed in 
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pluronic gel. Pluronic gel was able to increase the residence time of NP in the nasal cavity but 
decreased the migration of NP to the brain due to gel viscosity [218]. Chitosan NP have been 
also investigated as a delivery system to enhance bromocriptine brain targeting efficiency 
following intranasal administration. Bromocriptine NP were able to reverse haloperidol-
induced catalepsy and akinesia in mice, the nanoencapsulated drug being more effective than 
bromocriptine in solution. Moreover, a significant increase in bromocriptine brain uptake was 
observed after the intranasal administration of the radiolabeled drug nanoencapsulated in the 
mucoadhesive NP suggesting a direct nose to brain transport bypassing the BBB [208]. 
Yang et al. prepared PLGA NP loaded with L-DOPA methyl ester/benserazide and tested its 
efficacy after subcutaneous administration in the 6-OHDA toxic lesion PD model in rats. NP 
significantly reduced the axial, limb, orolingual and locomotive dyskinesias compared to the 
free drug [217]. 
Tsai et al. prepared tripalmitin and hydrogenated soybean phosphatidylcholine solid lipid NP 
to improve apomorphine oral bioavailability and brain distribution [230]. Glyceryl 
monostearate or polyethylene glycol monostearate were used as emulsifiers in SLN 
preparation. Pharmacokinetic studies comparing the oral formulation administration with the 
i.v. drug injection were done in rats. Both systems increased 12- to 13-fold apomorphine oral 
bioavailability compared to the control. Drug brain distribution studies after oral 
administration of the formulations indicated detectable apomorphine concentration in the 
cerebellum, brainstem and striatum. Moreover, both formulations improved motor behavior of 
6-OHDA rats the polyethylene glycol monostearate NP being more efficient than the glyceryl 
monostearate ones [230]. 
Solid lipid nanoparticles [236] and polymer-lipid hybrid NP [79], both with modified surface, 
have recently been proposed for Pardeshi as intranasal nanocarriers for ropinirole 
hydrochloride. Nanovectors demonstrated good retention of the formulations with no signs of 
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damage to nasal mucosa. In vivo pharmacodynamics studies comparing the nanosystems with 
the commercial oral formulation demonstrated the efficacy of the nanovectors. 
B) Nanoparticles for growth factor and peptides delivery 
A novel biodegradable brain drug delivery system was proposed by Hu et al., who developed 
lactoferrin conjugated polyethylene glycol PLGA (PEG-PLGA) NP encapsulating the 
fluorescent coumarin-6 [226]. In vitro studies showed that clathrin-related endocytosis 
mediated NP incorporation by bEnd.3 cells. Following i.v. administration of lactoferrin-NP, 3 
times more fluorescent probe was found in the straiatum and substantia nigra than with NP 
administration. To explore the utility of the delivery system in PD, the cytoprotectant peptide 
urocortin was incorporated into the Lactoferrin-NP. I.v. administration of the nanosystem 
significantly attenuated the 6-OHDA-induced lesion improving rotational behavior, striatal 
DA content and TH-immunoreactivity [226]. 
The lectin, odorranalectin was conjugated to PEG-PLGA NP to improve nose to brain drug 
delivery [73]. Odorranalectin bioactivity was maintained after NP preparation as confirmed 
by an in vitro haemagglutination test using red blood cells. DiR fluorescent tracer was 
incorporated to the odorranalectin-NP to investigate the nose-to-brain delivery of the system 
by in vivo fluorescence imaging. The brain uptake of DiR loaded NP was effectively 
increased by odorranalectin. In order to study the efficacy of this nanomedicine in PD, 
urocortin was used as drug model and nanoencapsulated in OL-NP. The intranasal 
administration of the system enhanced urocortin neuroprotective effect in hemiparkinsonian 
6-OHDA rats [73]. 
Nerve growth factor (NGF) is a potential disease modifying therapeutic protein for AD due to 
its neurotrophic activities on basal forebrain cholinergic neurons. However, its clinical 
application is hindered by major problems associated with effective CNS delivery and adverse 
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effects. In this connection, Kurakhmaeva et al. investigated NGF brain delivery after iv 
administration using PBCA NP coated with P80 and the pharmacological efficacy of this 
delivery system in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model 
[216]. NGF transport through the BBB was analyzed by direct NGF measurement in the 
mouse brain. In addition, the nano-formulation significantly reduced basic PD symptoms such 
as oligokinesia, rigidity or tremor [216]. 
C) Nanoparticle-based gene therapy 
Gene therapy has been extensively explored in the PD context and many clinical trials using 
gene therapy are under investigation. In parallel to existing viral vectors, NP can be used as 
non-viral vectors for brain gene delivery. With this purpose, Huang et al. examined the 
neuroprotective effects of lactoferring conjugated-PANAM/PEG NP encapsulating hGDNF 
gene using a multiple-dosing regimen i.v. administered in two different rat PD models. NP 
significantly improved locomotor activity, reduced dopaminergic neuronal loss and enhanced 
monoamine neurotransmitter levels in both animal PD models [296, 297]. Recently, the same 
author prepared NP conjugated to Angiopep, a ligand that specifically bind to low-density 
lipoprotein receptor-related protein which is overexpressed on the BBB. Angiopep was 
conjugated to dendrigraft poly-L-lysine, a poly-L-lysine-based dendrimer, via PEG. Angiopep 
conjugated NP exhibited higher cellular uptake and gene expression in brain cells compared 
to unmodified counterpart. Best improved locomotor activity and apparent dopaminergic 
neuron recovery was observed after five i.v. injections of hGDNF-NP in the rotenone-induced 
PD model [98]. 
F) Nanoliposome-based gene therapy; the Trojan horse nanoliposome technology 
The group of Pardridge et al. has great experience in transgene delivery to the brain following 
i.v. administration of PEGylated immunonanoliposomes. This technology has been validated 
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in multiple animal models in mice, rats and monkeys demonstrating that Trojan horses can be 
administered chronically without toxicity or immune reactions. Regarding PD, they worked 
with TH and GDNF plasmids. These authors demonstrated that it is possible to normalized 
TH activity in the 6-OHDA depleted striatum and to reverse motor impairment by i.v. 
administration of PEGylated immunoliposomes encapsulating TH plasmid targeted with the 
OX26 murine monoclonal antibody to the rat TfR [249]. This technology was further 
improved with the use of a TH plasmid engineered with a brain-specific promoter to avoid 
ectopic transgene expression [251]. When a GDNF plasmid was used, a near complete rescue 
of experimental PD in rats was observed. The GDNF transgene expression was under the 
influence of the rat tyrosine hydroxylase (TH) promoter to express the neurotrophic factor 
only in the regions of the brain that express TH gene. Trojan horse liposomes were able to 
reduced 87% apomorphine-induced contralateral rotation and 90% amphetamine-induced 
ipsilateral rotation. In addition, motor function improvement correlated with a 77% increase 
in striatal TH activity [250].This technology could soon be translated to humans. 
E) Nanoemulsion gel for dopamine agonist delivery 
Transdermal nanoemulsion gel containing ropinirole has been designed for the efficient 
treatment of PD [298]. Pharmacokinetic studies revealed a greater and more extended 
ropinirole release from the nanoemulsion compared to the conventional gel and to the orally 
administered marketed drug tablet suspension. Drug bioavailability was enhanced more than 
two fold with the nanoemulsion gel formulation. Ropinirole loaded nanosystem efficacy 
following transdermal administration was evaluated in terms of oxidative stress marker levels 
in the 6-OHDA-lesioned striatum of rats. A significant increase in thiobarbituric acid reactive 
substances and in reduced glutathione and catalase activity were reported demonstrating its 
significant value in clinical PD treatment [298]. 
3.3.3 Invasive methods; local administration 
50 
 
GDNF is one of the most promising candidates for PD treatment given its well-known 
neuroprotective and neuroregenerative properties. In order to resolve the crucial delivery 
issues poses by neurotrophic factors, several groups, including ours, have administered GDNF 
locally to the striatum using biodegradable and biocompatible microparticles in different 
animal models of PD [299-301]. Functional recovery in addition to increase in striatal 
dopaminergic innervation has been reported [299-301]. Regarding nanotechnology strategies 
for local administration of GDNF, Yurek et al. published several studies using GDNF plasmid 
DNA compacted into NP using a polycation-like 10 kDa polyethylene glycol (PEG)-
substituted lysine 30-mers (see Table 3). In the first paper the authors combine this nonviral 
gene therapy with neural grafts in order to improve the survival of the grafted cells and the 
recovery of parkinsonian rats [238]. Compacted DNA NP locally implanted into the striatum 
overexpressed GDNF in the lesioned striatum to levels able to provide support to grafted 
cells. Authors showed that survival of grafted cells was improved. In addition, a more 
extensive fiber outgrowth from the graft with more dopaminergic cells was found. This led to 
a better functional recovery by the animals [238]. The same group observed a sustained 
GDNF overexpression after single injections of rat GDNF DNA NP into the striatum [239]. 
Recently, in order to achieve a long-term transgene activity in the brain GDNF plasmids were 
optimized. GDNF plasmid were compacted into DNA NP and injected into the brain 
achieving a long-term expression in the brain [237]. 
The site-specific delivery of DA from an intracranial nano-enable scaffold device (NESD) 
implanted in the frontal lobe parenchyma was proposed for Pillay et al. [302]. The NESD is 
composed of a binary crosslinked alginate scaffold containing cellulose acetate phthalate NP 
loaded with DA. The in vivo evaluation of the device upon implantation into the rat brain 
demonstrated that the system was biocompatible, biodegradable and had a positive effect on 
DA concentration in the brain [302]. 
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4 CURRENT CHALLENGES FOR THE CLINICAL DEVELOPMENT OF 
NANOMATERIALS 
Nanotechnological application to diagnose and treat medical disorders shows great promise to 
provide powerful tools in medicine. However, after nearly twenty years of research, 
nanotechnology approaches to brain drug delivery remain under study. One of the reasons 
responsible for this is the BBB mentioned previously. But in addition to this there some more 
challenges that researchers need to face in order to make nanomaterials safe and effective.  
4.1 Toxicity of nanomaterials 
While the application of nanomaterials in biomedical field is a increasing, their potential 
hazard for human health is still under study, due to their special physicochemical properties, 
mainly their possible toxic effects on CNS [303]. Generally, the combination of various 
factors are responsible for the harmful effects of nanomaterials. Among them, the high surface 
area and the intrinsic toxicity of the surface are particularly important [304]. Therefore, the 
assessment of the neurotoxic effects of these nanomaterials on CNS function is a must, as the 
mechanisms and pathways through which nanomaterials may cause their toxic effects remain 
unidentified. When drugs are delivered to the brain, we have to bear in mind that many of the 
drugs that can be distributed in the CNS cause unwanted neurotoxicity by themselves [305, 
306]. Also, recent investigations suggest that several nanomaterials, such as polysorbate 80-
coated NP, are able to cross BBB through either oral or i.v. administration and accumulate in 
the brain [121, 200, 202]. As these NP penetrate the BBB, they could cause side effects after 
affecting the BBB function and brain physiology. So far, there are not so many reportsthat 
explain neurotoxicity of NP both in vitro and in vivo [303, 307]. 
4.1.1 In vitro toxicity of nanomaterials 
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Several research groups have reported potential toxicity of nanomaterials on different types of 
cells in vitro [202, 308-310]. Ever since Greene and Tischler used PC12 neuronal phenotype 
cells as a model for neurobiological and neurochemical studies, this cell line has become the 
most widely used cell model for nanoparticle neurotoxicity studies [311]. Wang et al. 
observed how the expression of dopaminergic system-related genes in PC12 cells induced by 
metallic nanoparticles made of Cu and Mn changed, inducing DA depletion in this cell line 
[312]. The results suggested that Mn and Cu NP could produce dopaminergic neurotoxicity 
and might share some common mechanisms associated with neurodegeneration. Hussain et al. 
observed similar results reporting that the exposure of PC12 cells to manganese oxide 
particles could deplete DA, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA) in a dose-dependent manner and increase the production of reactive oxygen species 
(ROS), while cytotoxic silver nanoparticles could produce cell shrinkage and irregular 
membrane borders [313]. In another study, Pisanic et al. showed that exposure to increasing 
concentrations of anionic magnetic nanoparticles (MNP) diminished the viability of PC12 
cells [310]. Wu et al. carried out studies to elucidate the toxicity of SiO2 nanoparticles, 
demonstrating that exposure to SiO2 decreased cell viability, increased levels of lactate 
dehydrogenase, triggered oxidative stress, disturbed cell cycle, induced apoptosis, and 
activated the p53-mediated signaling pathway in the PC12 cell line. Zhang et al. investigated 
and compared the concentration-dependent cytotoxicity of single-walled CNT (SWCNTs) and 
SWCNTs functionalized with polyethylene glycol (SWCNT-PEGs) in neuronal PC12 cells 
[314]. They found that SWCNTs elicited cytotoxicity in a concentration-dependent manner, 
and SWCNT-PEGs exhibited less cytotoxic potency than uncoated SWCNTs. Reactive 
oxygen species (ROS) were generated in both a concentration- and surface coating-dependent 
manner after exposure to these nanomaterials, indicating different oxidative stress 
mechanisms, and therefore suggesting that surface functionalization of SWCNTs decreases 
ROS-mediated toxicological response in vitro. In recent studies, Xue et al. demonstrated that 
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microglia secretion levels of TNF-alpha, IL-1beta and IL-6 were variably increased by SiO2, 
TiO2, hydroxiapatite (HAP) and Fe3O4 inorganic NP. They also observed that microglia-
derived soluble factors induced by TiO2-NP suppressed Th gene expression, and those 
induced by TiO2-NP and HAP-NP caused dysfunction and cytotoxicity in PC12 cells [315]. 
In addition to PC12 cell lines, other primary culture cell lines have also been used to assess 
the neurotoxicity of NP. To examine the possible neurotoxicity of the photocytotoxic material 
TiO2, Long et al. exposed brain cultures of immortalized mouse microglia (BV2), rat 
dopaminergic neurons (N27), and primary cultures of embryonic rat striatum to different 
concentrations (2.5 – 120 ppm) of the TiO2. This compound did not produce cytotoxicity in 
N27 cell line after 72 h exposure. Primary cultures of rat striatum exposed to the nanomaterial 
showed a reduction of immunohistochemically stained neurons and microscopic evidence of 
neuronal apoptosis after 6 h exposure. Furthermore, BV2 microglia showed an immediate and 
prolonged release of ROS. Microarray analysis on these TiO2-exposed BV2 microglia 
indicated up-regulation of inflammatory, apoptotic, and cell cycling pathways, and down-
regulation of energy metabolism. These results indicate that TiO2 is nontoxic to isolated N27 
neurons, but stimulates BV2 microglia to produce ROS and damages neurons at low 
concentrations in cultures of brain striatum, probably through microglial generated ROS 
[316]. Similar results were found by Wang et al., who observed that the proliferation rate of 
U87 glioma cell line was decreased when TiO2 nanoparticles were combined with UVA 
irradiation. Results from their work suggested that TiO2 induction of glioma cell apoptosis is 
associated with changes in the expression of genes encoding Bcl-2 family members [317]. 
Zinc oxide (ZnO) nanoparticles were also assessed for their neurotoxicity in mouse neural 
stem cells. Deng et al. found that ZnO nanoparticles induced cell apoptosis due to the 
dissolved Zn2+ in the culture medium or inside cells [308]. In another study, Locatelli et al. 
developed lipophilic Ag NP that were entrapped into PEG-based polymeric nanoparticles and 
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conjugated with the peptide chlorotoxin for the treatment of glioblastoma. Results from this 
study reveal that the uptake of Ag into the cells was improved up to 8.4 times with respect to 
the non-targeted NP. Furthermore, they also observed a greater cytotoxic effect on U87 
glioma cell lines [318]. 
4.1.2 In vivo toxicity of nanomaterials 
Cell cultures have been extensively employed to test the safety of nanomaterials [319]. 
However, these methods only explore some of the aspects of the biological system, whereas 
the in vivo machinery is far more complex with interdependent pathways that cannot be 
captured in a single in vitro experiment [320]. As a result, nanotoxicology is gaining a lot of 
interest in order to assess the unpredictable effects that these nanostructures might exert in 
biological systems. Even though we have described some of the in vitro studies that 
demonstrate adverse effects of NP on neuronal or glial cells, effects of NP on the CNS in vivo 
are still not well known.[321] Therefore, further in vivo studies are needed to provide vital 
information to assess the neurotoxic effects of NP [322, 323]. 
There are many biodegradable and biocompatible polymers which have been approved by 
FDA for clinical application. However, the brain targeting delivery of these polymer-based 
nanoparticles is still limited. Liu et al. evaluated the in vivo toxicity and immunogenicity of 
poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) NP conjugated to WGA after repeated 
intranasal administration [324]. These NP induced slight oxidative stress and excitotoxicity, a 
process by which nerve cells are damaged by excessive stimulation by neurotransmitters, as 
evidenced by increased glutamate levels in rat brain and enhanced LDH activity in the rat 
olfactory bulb.  
NP made of noble metals have been also used in brain delivery for theranostic purposes [317], 
[325-327]. Neurotoxicity of silver in the brain has already been reported after systemic, 
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intracerebral and intranasal administration [321, 325, 328, 329]. In recent studies, Liu et al. 
studied the effects of the Ag-NP on hippocampal synaptic plasticity and spatial cognition in 
rats after two-week exposure to Ag-NP through nasal administration. They observed the 
formation of an elevated amount of ROS in the hippocampus, which might be the reason for 
the neural damage caused by silver nanoparticles [325]. Prasek et al. studied the neurotoxicity 
of Pt-NP as potential brain cancer treatment. After the administration of Pt-NP hydrocolloids 
at concentrations of 1 to 20 μg/ml to chicken embryos at the beginning of embryogenesis, 
they observed that there was no change in the number of cells in the brain cortex of the 
chicken embryo; however, analyses of brain tissue ultrastructure reported mitochondrial 
degradation [326]. 
Xu et al. recently observed that the i.v. administration of TiO2 NP to mice could induce 
damage in the brain. More precisely, when mice were treated with a single dose of TiO2 (1387 
mg/kg BW) the brain tissue showed neuronal cell degeneration and vacuoles were observed in 
the hippocampus, which is indicative of fatty degeneration in the hippocampus [330]. 
To sum up, the above mentioned studies indicate that there are potentially harmful effects of 
nanomaterials to biological systems. Furthermore, the toxicity of these nanomaterials after 
their BBB crossing have not been fully studied. All these studies support the need for further 
research on the acute and long-term effects of nanomaterials both in vitro and in vivo, as their 
toxicity has been mostly studied in mice. More studies will determine if these results can be 
extrapolated to humans. 
4.2 Fate of nanomaterials 
The development of nanomaterials which specifically target the correct population of diseased 
cells sparing healthy ones is one of the most challenging tasks when aiming to treat disorders 
in the CNS, for example, to target toxic drugs at brain tumors. 
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With nanotechnology, intelligent drug delivery systems overcome the difficulty of these 
required tasks.  
When NP are designed for clinical applications, we should bear in mind that they can undergo 
important modifications after their systemic administration. More precisely, the nonspecific 
interaction between the NP surface and proteins that circulate in the blood, that leads to the 
opsonization of their surface. This forms the “corona”. The opsonization of the NP by these 
proteins significantly changes the original properties of the NP, determining their removal 
from the blood by the reticuloendothelial system (RES), mainly in liver and spleen. However, 
there are common approaches to escape RES and thus avoid premature clearance of the NP. 
Coating the NP surface with different hydrophilic surfactants, such as PEG and polysorbates, 
the formulation of NP with neutral surface charge, or the use of small sized nanoparticles 
(e.g., <80 nm) are some examples to achieve this goal [331]. NP that present these features, 
called “stealth” NP, circulate in the blood for a longer time , and their surface may be 
modified to cross the BBB [332]. 
The corona on the shell of NP determines not also their clearance but also their distribution in 
different compartments and their ability to cross from one to another or their successful 
uptake by cells [333]. The formation of the corona supports the idea that unmodified NP do 
not exist in vivo, because as soon as they are administered the adsorption of proteins present 
in the blood with more affinity for the particle surface will immediately modify them, thus 
forming a weak layer (soft corona) or a more or less tightly bound layer (hard corona) [334, 
335]. The binding of different proteins to the NP shell not only influences their surface charge 
of the NP, but also modifies their total size and can hide functional groups. This means that 
the originally bound targeting groups for the crossing of the BBB may be covered. The 
stability of the corona attached to the surface of the NP is time-dependent because as long as 
the NP spend longer time travelling through the body, the protein shell will be exchanged as 
the particles will pass through different cell layers more often [336]. Furthermore, it has also 
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been observed that the corona may not play a role only in cellular uptake, but can also activate 
the complement and blood clotting processes, which might not be desired [337]. 
It is worth noting that among the in vitro studies performed to study how the NP translocate 
into the brain, there is no single one that studies the surface modification that NP undergo 
after their administration and how these modifications affect the crossing of the BBB. 
Moreover, once NP are crossing the BBB, the corona they show when they exit towards the 
brain might be different depending on the process that took place, namely, endocytosis, 
transcytosis and exocytosis, and, thus, produce additional either beneficial or toxic effects on 
neurons. As a result, there is much further research to be done in this field in order to 
understand the mechanisms underlying in this post-administration modification process.  
4.3 Commercialization problems 
Commercialization of highly innovative products has always represented a great challenge, 
particularly when it comes to high risk/high return products. In the case of nanomedicine, 
multiple barriers delay going on the market. So far, the process of NP-based therapeutics 
commercialization has been long and hard. The most important challenges and risks are 
summarized in Figure 4 and will be discussed below [2, 338-340]. 
Some of the problems that pharmaceutical companies are facing are associated with the NP 
manufacturing process. Issues to be solved are the lack of quality controls, the high 
manufacturing costs, scalability issues or problems related to the production rate enhancement 
among others [340]. Another important challenge is the insufficient evidence from in vivo 
studies, the relatively few clinical trials investigating NP that are currently under way and the 
few commercial products based on nanotechnology that are currently on the market [2, 338, 
340]. Unfortunately, most of the results presented in this review, have been obtained in in 
vitro models and are still at the concept level. Therefore, the potential of many nanomedicines 
is yet to be determined. In addition, as mentioned earlier in this review, little is known about 
nanomaterial and nanoparticle safety. Scientists and regulators are struggling to characterize 
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these materials in an effort to create appropriate toxicological testing and assessment tools. 
Another obstacle to clinical translation is the FDA-approval process. Nanomedicines are the 
most heavily regulated consumer products throughout the pre-and post-marketing phases. The 
requirements set by the FDA for clinical trials with nanotherapeutics are extremely complex 
and demanding [338-340]. The approval procedure and regulations of medical products based 
on nanotechnology are different from those other industries using nanotechnology with no 
regulatory limitations. On top of that, reforms at the Patent and Trademark Office are needed 
to create a robust patent system that helps any commercialization effort and avoids confusion 
and delay [340]. Overlapping with patents can be also taken into consideration. Finally, 
attracting investment for nanomedicine research is also particularly challenging [338, 340]. 
Commercialization of nanomedicine is currently driven by small and medium-size companies 
and by startups. Universities are also pushing for funding to adapt basic nanomedical research 
into real products. One the other hand, big pharmaceutical companies are very cautious about 
making large investments in nanotherapeutics because positive returns occur only in the long 
term. They are also concerned about whether the FDA will be even stricter in regulating 
nanomedicines in the future. 
In spite of all these obstacles to the growth of nanotechonology for medical applications, 
investment in nanomedicine is expected to increase. Doxil or Ambrasane success among 
others have made the risk/reward ratio more appealing and have impacted the healthcare 
system. Moreover, since nanoformulations of older therapeutics may be patentable, 
nanomedicine is expected to prolong the economic life of proprietary drugs creating more 
revenues. It is also estimated that novel or reformulated nanotherapeutics will disrupt the 
generic drug market as well [338, 340]. All of these have generated great expectations in big 
pharmaceutical companies. In summary, there are many problems that need to be overcome, 
but this is an area that still shows enormous potential.  
59 
 
5 CONCLUSIONS AND FUTURE DIRECTIONS 
Nanotechnological application to medical problems aims to increase expectations for the 
delivery of drugs to diagnose and treat brain-related diseases like neurodegeneration and 
cerebral tumors. These diseases are nowadays a major medical challenge and they are 
becoming more prevalent in society as the population become older. Remarkably, as this 
paper has shown, nanotechnology has proven to make possible the transport of many drugs 
across the BBB in various models of neurodegenerative disorders and brain tumors, one of the 
current obstacles faced by conventional therapeutics. In addition, nanotechnology has 
demonstrated potential to enhance the sensitivity of current diagnostic tools and to be more 
effective than conventional therapies with fewer side effects. Although promising, these 
findings should be considered preliminary since few nanomedicine candidates have reached 
clinical practice and its potential is yet to be determined.  
At the moment the mechanism of drug transfer into the brain mediated by NP appears to be 
characterized. However, the further fate of NP in the brain and how to target specific neuron 
populations still requires much more basic research. On the other hand, the amount of drug 
that enters the brain remains low (1-2% approximately). Although this is significant enough to 
exert a beneficial effect, the remaining question is how to maximize the amount of drug that 
reaches the brain in order to avoid NP accumulation in other organs. Moreover, even though 
nanotechnology is rapidly advancing rigorous safety studies to ensure public acceptance of 
nanotechnology are needed.  
Finally, nanotechnology must overcome difficulties related to its commercialization process 
since this area is still in its infancy. Attracting investment by big pharmaceutical companies 
for nanomedicine research is also particularly challenging due to the risk associated to the 
commercialization of this highly innovative products. In this sense,  cooperation between 
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doctors, patients, researchers, technologists, economists, investors, healthcare providers, , in 
order to reduce the high risk associated to investments in nano-based drugs with the final goal 
of providing many benefits for patients is crucial and must be facilitated.  
Hopefully, nanomedicine will eventually bring hope for better diagnosis and management of 
brain disorders making therapies far more effective. 
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